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ABSTRACT 
Head and neck cancer accounted for 3.3% of incident malignancies and 2.0% of cancer-deaths in 
the US in 2009, the majority of which are squamous in origin. Thus, there is a need for novel 
biomarkers for early detection and prognosis of squamous cell carcinoma of the head and neck 
(SCCHN). MicroRNA-137 plays a role in cell cycle control through negative regulation of Cdk6, 
and has been reported to undergo promoter methylation in oral squamous cell carcinoma. Oral 
rinse is a non-invasive mode of DNA collection, which may have some utility in detection of 
promoter methylation. The primary goals of this research were to determine if miR-137 promoter 
methylation occurs in all SCCHN, including pharyngeal and laryngeal tumors, and whether it is 
detectable in oral rinse samples; and to assess miR-137 promoter methylation as an etiologic and 
prognostic biomarker for SCCHN.  DNA was extracted from oral rinses from 99 SCCHN 
patients and 99 cancer-free control subjects and from tumor tissue of 67 SCCHN patients; paired 
oral rinses and tumor tissue was available for 64 of the SCCHN patients.  Promoter methylation 
status of miR-137 was determined by methylation-specific PCR.  We identified a strong 
association between miR-137 promoter methylation detected in oral rinses and SCCHN (OR = 
4.80, 95% CI: 1.23-18.82).  There was a strong positive association between female gender and 
miR-137 promoter methylation in oral rinse from SCCHN patients (OR = 5.30, 95% CI: 1.20-
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23.44) and an inverse association with body mass index (OR = 0.88, 95% CI: 0.77-0.99).  
Promoter methylation of miR-137 in tumor tissue was associated with poorer overall survival 
(HR = 3.68, 95% CI: 1.01-13.38). In spite of its low sensitivity (21.2%), miR-137 methylation 
detected in oral rinse may have future value in methylation panels for early diagnosis of SCCHN 
due to its high specificity (97.0%) and occurrence in early stage disease; and its detection in 
tumor tissue has promise as a prognostic marker. The identification of novel diagnostic and 
prognostic biomarkers for SCCHN such as miR-137 promoter methylation will significantly 
impact public health through the reduction of morbidity and mortality that occurs as a result of 
this disease. 
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1.0  INTRODUCTION 
Head and neck cancer is a broad classification for a heterogeneous group of malignancies arising 
in the upper aerodigestive tract.   It is estimated that head and neck cancer resulted in 48,010 
cases and 11,260 deaths in the United States in 2009 [1], and more than 500,000 annual cases 
and 300,000 deaths globally [2].  Squamous cell carcinoma of the head and neck (SCCHN) 
makes up the majority, representing 93% of all head and neck cancers [3].  Although head and 
neck cancer only accounts for 2% of US and 4.5% of global cancer deaths, it bears substantial 
morbidity and remains a very preventable cancer, due to its strong association with alcohol and 
tobacco use.  
Epigenetic changes are heritable but reversible genetic modifications that affect gene 
expression without altering the DNA sequence [4].  DNA methylation is a crucial epigenetic 
process in controlling gene transcription.  Methylation occurs at dinucleotides in which cytosine 
is upstream and adjacent to guanine, termed CpGs.  These CpG dinucleotides are not randomly 
distributed throughout the genome, but rather are concentrated in CpG rich regions referred to as 
CpG islands that occur disproportionately in the 5’ promoter region of genes.  When methyl 
groups are covalently attached to CpGs in the promoter regions of genes (termed 
hypermethylation) it generally results in transcriptional silencing.  Promoter methylation is at 
least as common as mutations in tumor suppressor gene inactivation and is considered to be a 
major event in carcinogenesis, including SCCHN.  It occurs at various stages of cancer 
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development, and is often an early event.  Epigenetic alterations can arise as a result of 
environmental exposures, such as tobacco and alcohol, although the precise mechanisms remain 
poorly understood [5]. 
MicroRNAs are small, non-coding RNA molecules, averaging 22 nucleotides in length, 
that negatively regulate gene expression post-transcriptionally by binding target mRNA and 
inducing degradation or translational silencing. MicroRNAs affix to their targets with varying 
degrees of complementarity, and as a result, a single microRNA can affect the expression of 
many genes [6].  MicroRNA expression can be controlled through epigenetic mechanisms, with 
an estimated 10% regulated by DNA methylation [7].  As with protein coding genes, they can 
function as either tumor suppressors or oncogenes:  those that regulate expression of proto-
oncogenes act as tumor suppressors, while those that target tumor suppressor genes can act as 
oncogenes if overexpressed.   Dysregulation of individual microRNA expression has been 
correlated with various solid tumors, including SCCHN, and with poorer prognosis for several 
cancers [8-19]. 
Early diagnosis of SCCHN is crucial in treatment of the disease, since 5-year survival 
declines with increasing stage and two-thirds of SCCHN patients are diagnosed with advanced 
stage disease [20].  Currently, no proven screening method exists aside from visual inspection.  
Due to early occurrence during carcinogenesis and the relative stability of DNA, methylated 
tumor suppressor genes have good potential as cancer biomarkers. MicroRNA expression shows 
more tumor-specificity than mRNA expression, suggesting that alterations affecting microRNA 
transcription, such as promoter methylation, may be more specific for tumor type than those 
affecting protein-coding genes.  Moreover, dysregulated expression of microRNAs has been 
reported to have prognostic implications. Promoter methylation can be detected by extracting 
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DNA from tumor tissue.  Additionally, use of oral rinse (mouthwash) for DNA collection is a 
non-invasive method that may have utility in detection of promoter methylation in upper 
aerodigestive tract tumors [21-26] and therefore has potential as a screening tool for SCCHN.  
MicroRNA-137 (miR-137) is embedded in a large CpG island and is located on 
chromosome 1p21.3 [17, 27].  A recent report observed hypermethylation and corresponding 
downregulation of miR-137 in a small clinical sample of oral squamous cell carcinomas (OSCC) 
[27].  One of the known targets of miR-137 is Cdk6, a key protein in cell cycle progression.  
Cdk6 forms a complex with Cyclin D1 that phosphorylates pRb, releasing E2F transcription 
factor, inducing transcription of proteins necessary for progression from G1- to S-phase of the 
cell cycle.  Downregulation of miR-137 results in overexpression of Cdk6, leading to increased 
cellular proliferation [17, 27]; and expression of miR-137 has been inversely correlated with 
cellular differentiation in gliomas [17], although it is presently unknown whether this 
involvement with differentiation extends to squamous epithelium of the head and neck.  
Furthermore, overexpression of Cdk6 has been reported in SCCHN [28-30]. It is because of its 
involvement in cell cycle control and its potential role in cellular differentiation, as well as its 
promoter methylation in OSCC, that leads us to study miR-137 promoter methylation in depth as 
a biomarker of SCCHN.  Exploration of new biomarkers such as this will aid in the search for 
better diagnostic and prognostic tools for early detection and treatment of SCCHN.  
The hypothesis driving this research, illustrated in Figure 1, is that alcohol and tobacco 
exposures can lead to epigenetic dysregulation and aberrant promoter methylation of miR-137, 
repressing its expression and resulting in increased cellular proliferation and loss of 
differentiation, thus contributing to the development of SCCHN.  The overarching objective of 
this research is to contribute to the vast, ever-growing body of biomedical science literature 
 4 
through the evaluation of miR-137 promoter methylation as a biomarker for SCCHN.  
Specifically, this research seeks to 1) assess miR-137 promoter methylation in oral rinse samples 
as a diagnostic biomarker for SCCHN and identify risk factors involved in its occurrence; 2) 
evaluate miR-137 promoter methylation as a prognostic biomarker of SCCHN; and 3) determine 
the predictive value of oral rinse for the detection of miR-137 promoter methylation in SCCHN 
tumor tissue using methylation-specific PCR. 
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Figure 1.  Biological model for hypothesized involvement of miR-137 promoter methylation in SCCHN 
oncogenesis 
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2.0  HEAD AND NECK SQUAMOUS CELL CARCINOMA 
Head and neck cancer is a broad term applied to a heterogeneous group of malignancies arising 
in the upper aerodigestive tract. This encompasses cancers of the oral cavity, oropharynx, 
hypopharynx, nasopharynx, nasal cavity, paranasal sinuses, and larynx (Figure 2).  It is estimated 
that approximately 93% of these are squamous cell carcinoma of the head and neck (SCCHN) 
[3].  The focus of this report will be on SCCHN of the oral cavity, pharynx (oropharynx and 
hypopharynx), and larynx; nasopharyngeal, nasal cavity and paranasal sinus cancers will not be 
discussed, since they are generally considered to be of a different etiology and are typically 
evaluated as a separate clinicopathological entity. 
 
 
Figure 2.   Anatomy of the upper aerodigestive tract 
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2.1 EPIDEMIOLOGY OF HEAD AND NECK CANCER 
            2.1.1 Incidence and Mortality 
In 2009, it is estimated that head and neck cancer accounted for 48,010 new cases and 11,260 
deaths in the United States alone [1].  This represents 3.2% of all incident cancers and 2.0% of 
all cancer-deaths annually in the US, excluding basal and squamous cell carcinomas of the skin 
[1].   Considered together, cancers of the oral cavity, pharynx and larynx comprise the 9th most 
common site for cancer incidence overall and are ranked 15th in cancer related deaths [1].  
Cancer of the oral cavity and pharynx accounted for 35,720 (74.4%) head and neck cancer cases 
and 7,600 (67.5%) deaths in the US in 2009 (excluding nasopharyngeal), while laryngeal cancer 
accounted for 12,290 (25.6%) of the cases and 3,660 (32.5%) of the deaths [1].  As a whole, head 
and neck cancer incidence and mortality have been declining over the past 2 decades, although 
this trend is not consistent across all ages and sites [31].  While rates of oral cavity and laryngeal 
cancers have gone down, they have remained stable for pharyngeal cancer.  As a result, 
pharyngeal cancer accounts for an increasing proportion of head and neck cancers.  Among 
adults less than 45 years of age, incidence of pharyngeal cancer has actually increased.  This is 
particularly true for cancers of the base of tongue and tonsils, which have risen an average of 2% 
and 4% per year, respectively [32]. 
  Head and neck cancer is more common in men than women.  In the US, males are 2.74 
times as likely as females to develop head and neck cancer, and 2.61 times as likely to die from it 
[1].  When considering site specific incidence, men are 2.41 times as likely as females to be 
diagnosed with cancer of the oral cavity and pharynx and 2.22 times more likely to die from it 
[1].  Laryngeal cancer is even more common in males: men are 4.19 times as likely to develop 
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laryngeal cancer and 3.82 times as likely to die from it [1].  In 2009, head and neck cancer 
ranked 8th among US men in cancer incidence, representing 4.6% of newly diagnosed cancers 
per year, and 11th overall in cancer mortality, accounting for 2.8% of US male cancer deaths [1].  
Among US women, it is the 13th most common cancer, representing 1.8% of annual incident 
cancer diagnoses, and ranks 17th in cancer deaths, accounting for 1.2% of US female cancer 
mortality [1].   
The incidence rate for oral cavity and pharyngeal cancer in the US is similar in African-
American and Caucasian females, whereas the incidence rate is 30% higher among African-
American males compared to Caucasian males [33].  With regard to laryngeal cancer, incidence 
rates among African-American males and females are double those of their respective Caucasian 
counterparts.  Oral cavity and pharyngeal cancer incidence rates are lowest among Hispanics, 
while Asians have the lowest incidence rates of laryngeal cancer [33]. 
Head and neck squamous cell carcinoma tends to occur in older adults.  The median age 
at diagnosis in the US is 62 years, although as previously discussed, incidence in adults younger 
than 45 years is increasing, particularly for cancer of the tonsil and base of tongue [20, 32-34].   
Globally, head and neck cancer is more common than it is in the United States.  In 2002 
there were an estimated 563,826 new cases of head and neck cancer (excluding nasopharyngeal), 
representing 5.2% of all incident cancers, and 301,408 deaths, representing 4.5% of the world 
cancer mortality [2].  Cancer of the oral cavity accounted for 274,289 (48.6%) global head and 
neck cases and 127,459 (42.3%) deaths; pharyngeal cancer accounted for 130,296 (23.1%) cases 
and 83,723 (27.8%) deaths; and laryngeal cancer accounted for 159,241 (28.2%) cases and 
89,956 (29.9%) deaths.  
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            2.1.2 Staging and Survival 
Overall 5-year survival for head and neck cancer in the United States is approximately 60% and 
has remained virtually unchanged over the past 3 decades [20].  Despite therapeutic advances, 
there have been no significant improvements in survival for laryngeal cancer compared with the 
1970s, and only a slight significant gain for cancers of the oral cavity and pharynx [3].  However, 
there is substantial variability in survival by site.  Overall 5-year survival rates by site range from 
85.6% for cancer of the lip to 33.3% for hypopharyngeal cancers (Table 1) [3].  Distribution of 
stage at diagnosis also varies by site, with lip cancers being most likely to be diagnosed at an 
early stage while cancers of the hypopharynx are the most frequently diagnosed at later stages 
(Figure 3) [3], although this does not sufficiently explain the survival discrepancies.  Variation in 
adjacent structures at each site may offer further explanation for the prognostic differences 
between tumor sites. 
 
Table 1.  US head and neck cancer 5-year survival by site and stage, for year of diagnosis 1998-1999  
 
 Percent 5-Year Survival 
Site Overall Local Regional Distant 
Lip 85.6 89.6 82.7 40.0 
Oral Cavity 56.7 72.0 43.8 35.2 
Oropharynx 50.6 61.0 50.6 30.2 
Hypopharynx 33.3 56.0 34.6 12.9 
Larynx 62.0 74.3 53.2 38.3 
 
Data source: Carvalho AL (2005) [3] 
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Figure 3.  Head and neck cancer stage at diagnosis by site in the US, 1998-1999 
Data source: Carvalho AL (2005) [3] 
 
In the United States, sociodemographic disparities exist with respect to SCCHN survival.  
For cancers of the oral cavity and pharynx, the 5-year survival for African-Americans is 40.6% 
compared to 62.0% for Caucasians [35].  Likewise, 5-year survival for laryngeal cancer among 
African-Americans is 50.1% versus 66.0% for Caucasians [35].  Also, men have poorer survival 
rates than with women. Contrasted with women, the 5-year survival for men is 5.1% and 6.3% 
lower for cancers of the oral cavity/pharynx and larynx, respectively [35].  
Clinical stage and treatment are independent predictors of prognosis for SCCHN patients.  
Compared with treatment by surgery or combination surgery and radiotherapy, primary 
radiotherapy is associated with lower survival rates [3].  Higher TNM stage at diagnosis is 
associated with poorer outcome [3]. Approximately two-thirds of head and neck cancer patients 
present with regional lymph node involvement and about 10% with distant metastases [20]. The 
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presence of cervical lymph node metastasis is one of the most powerful predictors of prognosis 
[36, 37], with these patients experiencing a 50% reduction in 5-year survival [38]. Additionally, 
when extra-capsular spread (ECS) of lymph node metastasis occurs, prognosis worsens, with 
increased rates of local and distant metastasis and further declines in survival [38].  ECS occurs 
in 23% of positive lymph nodes < 1 cm, 39%-59% of nodes < 3 cm and 60%-100% of nodes > 3 
cm [39-43].  Perineural spread occurs in 2.5%-5% of cases and has been associated with poorer 
prognosis [44]. Histologic tumor grade [45], extent of necrosis [45], lymph node burden (number 
of positive nodes) [45] and positive surgical tumor margins are also correlated with outcome [46-
48]. 
At least 50% of patients with locally advanced SCCHN experience recurrence, generally 
within 2 years of treatment [20].  Additionally, second primary head and neck tumors commonly 
occur following an initial head and neck primary, developing in approximately 15% of primary 
head and neck cancer patients at a rate of 3-5% per year [34, 49].  Tumor recurrence or 
development of a second primary is a major reason for treatment failure and adversely impacts 
long-term survival [50, 51]. 
            2.1.3 Risk Factors 
            2.1.3.1 Tobacco 
Cigarette smoking has been identified as the chief avoidable cause of death [52] and is 
considered to be the major risk factor for SCCHN in the United States.  It was first linked to oral 
squamous cell carcinoma (OSCC) in the late 1950s by Ernst Wynder and colleagues in a 
landmark case-control study [53].  These findings were validated 1 year later by a large cohort of 
187,783 men reporting increased risk of mortality from SCCHN for cigarette smokers compared 
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to non-smokers [54].  Since then, numerous studies have replicated these findings, establishing 
the relationship between smoking and SCCHN [55-62]. This is recognized by the International 
Agency for Research on Cancer (IARC), which considers smoking to be a causal factor for 
cancer of the oral cavity, pharynx and larynx [63].  Other forms of tobacco consumption have 
also been associated with SCCHN, including cigar and pipe smoking [53, 55, 59, 61, 64-66] and 
smokeless tobacco [67-70].   
There is a linear dose-response relationship between cigarette smoking and SCCHN, for 
which duration of use is more important than the exposure intensity, although both matter [33].  
However, dose-response alone does not sufficiently explain global variation in SCCHN rates, 
suggesting that other risk factors may interact with tobacco use [71].  There is about a 3- to 10-
fold increase in risk of developing SCCHN among smokers compared with never-smokers [71], 
and an estimated 5- to 25-fold greater risk for heavy smokers [72].  For former smokers, there is 
an inverse relationship between time since quitting smoking and risk of SCCHN [55, 57-59, 61, 
62, 66], although their level of risk will never return to that of a never-smoker.  In addition to 
initial primary tumors, tobacco use is associated with development of second primary tumors of 
the head and neck [73, 74]. 
More than 60 carcinogens have been identified in cigarette smoke, including polycyclic 
aromatic hydrocarbons (PAH), nitrosamines, aromatic amines, aldehydes, volatile organic 
compounds, metals and others [75].  The majority of the carcinogenic effect contained in 
cigarette smoke is derived from the particulate fraction of the product [33].  Of the pro-
carcinogens, PAHs such as benzo[α]pyrene are the most potent in burnt tobacco, while 
nitrosamine metabolites, particularly nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3 
pyridyl)-1-butane (NNK), are the strongest in smokeless tobacco, although both are present in 
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each form [76, 77]. Procarcinogens require metabolic activation by phase I xenometabolic 
enzymes in order to exert their carcinogenic effect, primarily through the formation of DNA 
adducts resulting in accumulation of genetic insults [71, 76, 78].  In addition, cigarette smoke 
contains co-carcinogens and tumor promoters, which do not directly act on DNA but can cause 
diffuse hyperplasia or act through epigenetic mechanisms such as aberrant DNA methylation 
[76, 78].   
Furthermore, cigarette smoke inhibits the metabolism and storage of folate [79]. Nitrates, 
nitrous oxide, cyanates and isocyanates found in tobacco smoke have been shown to transform 
folate into a biologically inactive compound [80, 81].  Studies have observed reduced serum 
folate levels in smokers relative to non-smokers [82, 83].  Folate deficiency can result in 
chromosomal damage through impaired nucleotide synthesis and aberrant DNA methylation [84, 
85]. 
            2.1.3.2 Alcohol 
Globally, an estimated 389,100 cases of cancer per year are attributable to chronic alcohol 
consumption, accounting for 3.2% of all incident cases (5.2% of all cases in men and 1.7% in 
women), with a corresponding 232,900 deaths [86].  Consumption of alcoholic beverages has 
been classified as a causal risk factor for cancer of the oral cavity, pharynx and larynx by IARC 
[87] and is considered to be a contributive factor in an estimated 75% of all cases [33].  
As with smoking, there appears to be a dose-response relationship between alcohol 
consumption and SCCHN [71, 88], with the highest risk found among the heavy drinkers (> 100 
g/day), having approximately 4- to 6.5-fold risk relative to non-drinkers [88].  Daily 
consumption of 50 g, the approximate equivalent of a half-bottle of wine, or more of ethanol 
increases the risk for cancers of the oral cavity, pharynx or larynx 2- to 3-fold compared to non-
 14 
drinkers [87, 88].  Consumption of 3 or more alcoholic beverages per day has been associated 
with SCCHN in non-smokers [53, 55, 57-59, 61, 62, 89, 90], indicating that alcohol acts as a risk 
factor independent of tobacco.  Additionally, alcohol is a risk factor for development of second 
primary tumors [73, 74].  Associations have been found with all types of alcoholic beverages, 
suggesting that ethanol or its metabolites are the primary carcinogen.  Theories regarding 
impurities or contaminants have been proposed but studies attempting to correlate specific 
beverage types with cancer risk have thus far been inconclusive due to inconsistent findings [33, 
71].  
Alcohol may exert some of its effect by acting as a solvent for tobacco carcinogens and 
facilitating the uptake of these compounds into the mucosa [71, 91].  However, this alone is not 
sufficient to explain its carcinogenicity.  As previously discussed, heavy alcohol consumption is 
still associated with SCCHN in non-smokers. Ethanol is classified as a human carcinogen by 
IARC [87]. Its carcinogenic effect likely stems from its primary metabolite, acetaldehyde, which 
has been recognized as a carcinogen in laboratory animals [78]. Acetaldehyde has been shown to 
interfere with DNA synthesis and repair.  It can bind proteins resulting in structural dysfunction, 
including enzymes involved with DNA repair (O6 MGMT), DNA cytosine methylation and anti-
oxidation (glutathione) [92, 93]; and has also been demonstrated to form DNA adducts with 
human cells in vitro and in chronically exposed lab rats [94].  The level of DNA adducts in 
lymphocytes among alcohol abusers is reported to be 7-fold that of non-drinkers [95].  
Furthermore, experimental models have shown that inhalation of acetaldehyde can cause upper 
aerodigestive squamous cell carcinoma and adenocarcinoma in laboratory animals [71].  
The major alcohol metabolizing enzymes are alcohol dehydrogenases (ADH), which 
oxidize ethanol to acetaldehyde, and aldehyde dehydrogenases (ALDH), which detoxify 
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acetaldehyde into acetate [87].  A variant allele of ALDH (ALDH2*2) encodes an inactive 
subunit of the enzyme and has an allele frequency of 28-45% in East Asian populations. 
Individuals homozygous for the variant rarely consume alcohol due to discomfort and toxic 
effects stemming from the enzyme deficiency, and therefore are difficult to study 
epidemiologically.  However, heterozygotes have 10% ALDH2 activity, and heterozygous 
drinkers have been shown to have 3-fold higher concentrations of salivary acetaldehyde 
compared with wild-type individuals [96] and an increased risk of upper aerodigestive tract 
cancers [87], further supporting the role of acetaldehyde in carcinogenesis. Studies on ADH1 
have been contradictory and therefore inconclusive [93]. 
Acetaldehyde concentrations found in saliva are high enough to enable it to act as a 
carcinogen [96-98].  In saliva, ethanol is metabolized to acetaldehyde by bacterial enzymes [93].  
Poor oral health further potentiates the risk associated with smoking and alcohol consumption 
[78], resulting in an increase of oral bacteria, and therefore elevated salivary acetaldehyde levels 
[99]. Smoking rapidly shifts the oral flora from gram-negative to gram-positive bacteria, which 
convert ethanol to acetaldehyde in higher quantities, leading to a 50-60% rise in acetaldehyde 
concentrations compared with non-smokers [100].  Additionally, Candida albicans, commonly 
found in the oral flora of smokers, is also able to convert ethanol to acetaldehyde [100].  Use of 
antiseptic mouthwash has been shown to decrease salivary acetaldehyde levels by 30-50% [97].  
Alcoholics with oropharyngeal cancer have been reported to have very high concentrations of 
acetaldehyde in their saliva [101]. 
As with smoking, another carcinogenic mechanism of alcohol consumption stems from 
nutritional deficiencies through interaction with folate and retinoid metabolism [93].  It can 
inhibit the absorption of folate, a key nutrient in the methylation process, and mediates the 
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inhibition of S-adenosylmethionine (SAM), the universal donor in methyl-transfer reactions, 
including DNA methylation [93]. Acetaldehyde has also been shown to hinder key enzymes in 
the DNA methylation process (DNA methyltransferases) in animal studies [102].   DNA 
methylation is an important epigenetic mechanism for regulation of gene expression and 
maintenance of chromosomal stability.  Aberrant methylation can result in increased expression 
of oncogenes (hypomethylation) or inhibition of tumor suppressor genes (hypermethylation).  In 
addition, chronic alcohol consumption depletes retinoids, which are fat-soluble A vitamins.  
Retinoic acid is of particular importance due to its role in cellular growth and differentiation 
[93].  In animal studies, reduced retinoic acid levels following chronic exposure to ethanol was 
associated with increased cellular proliferation and decreased apoptosis [103-105]. 
Alcohol consumption can also affect clinical outcomes from cancer.  It has been 
associated with accelerated metastasis in colon cancer patients [106].  This is likely due to 
immunosuppression and induction of angiogenesis through the stimulation of vascular epithelial 
growth factor (VEGF) production [93, 107].  Furthermore, ethanol can interact with 
chemotherapeutic drugs, reducing their efficacy and increasing side effects [93]. 
            2.1.3.3 Interaction of Smoking and Alcohol 
When alcohol and tobacco are used in conjunction, the effect is multiplicative [20, 108].  
Combined use of alcohol and tobacco account for 73% of oral and pharyngeal cancers in non-
Hispanic Caucasians and 85% in African-Americans [33]. As previously discussed, alcohol is 
believed to further potentiate the effects of smoking by acting as a solvent for tobacco 
carcinogens.  Conversely, smoking can enhance the carcinogenicity of alcohol by causing in a 
shift in oral flora, thus increasing the microbial conversion of ethanol to acetaldehyde. 
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            2.1.3.4 Human Papillomavirus 
Human papillomavirus (HPV) is associated with nearly all cervical and most anogenital cancers, 
and is now recognized as a risk factor for SCCHN [109]. Approximately 25% of SCCHN is 
associated with HPV infection; and 45%-60% of oropharyngeal carcinomas are HPV-positive, 
particularly those arising in the lingual and palatine tonsils [110, 111]. In contrast, the estimated 
prevalence of HPV in normal oral mucosa is 10% (95% CI: 6.1%-14.6%) [111]. HPV16 is the 
most prevalent subtype, accounting for 90%-95% of these tumors [112]. Individuals with 
seropositivity for HPV16 viral capsid protein antibodies have a 15-fold higher risk for SCCHN 
[113].  Furthermore, there is an increased risk of developing a second-primary SCCHN in those 
diagnosed with a cervical or anogenital primary cancer [114, 115], lending further support to an 
HPV etiology of a portion of the disease. 
HPV-positive SCCHN represents a distinct clinical subset of tumors.  In contrast to HPV-
negative cases, patients with HPV-positive tumors tend to be younger in age, are more likely to 
be non-smokers or non-drinkers and are more frequently immunosuppressed [20, 78].  
Morphologically, these tumors are more apt to have basaloid features and be poorly 
differentiated compared to HPV-negative cases [20, 72, 78].  However, patients with HPV-
positive SCCHN tend to present at a lower T-stage [72] and have better overall and disease-free 
survival compared to those with HPV-negative tumors [116]. 
            2.1.3.5 Other Risk Factors 
Other risk factors for SCCHN include dietary factors, environmental and occupational 
exposures, gastroesophageal reflux and infection with the human immunodeficiency virus.  
These risk factors account for a much smaller attributable risk of SCCHN relative to tobacco, 
alcohol, and HPV and are discussed in more detail in Appendix A.1.6. 
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2.2 FIELD CANCERIZATION 
Development of SCCHN is a multistep process involving accumulation of genetic and epigenetic 
alterations resulting in cellular dysregulation.  The epithelium of the upper aerodigestive tract is 
exposed and vulnerable to carcinogenic insult, particularly from tobacco and alcohol, resulting in 
an increased risk of developing multiple primary tumors.  According to the “field cancerization” 
model proposed by Slaughter and colleagues in 1953 [117], multiple cancers develop from 
distinct, unrelated clones arising due to accumulation of independent mutations associated with 
chronic exposure of the epithelium to environmental carcinogens.  It has since been 
demonstrated that second primaries distant from the original primary can be clonally related to it 
[118].  This theory has lead to the development of the “expanding fields” model, which proposes 
that a single stem cell in the basal layer of the epithelium undergoes a transformation, clonally 
expands, and gradually replaces the normal epithelium.  As cells within the expanding field 
acquire new alterations, various subclones develop within the field, which can eventually 
propagate into distinct but related tumors.  These models help to explain, in part, the high rate of 
local recurrences and development of second primaries associated with SCCHN. 
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3.0  EPIGENETICS 
Epigenetics are heritable but reversible changes in gene expression due to genetic modifications 
that do not alter the DNA sequence [4].  These alterations include DNA methylation and histone 
modifications (Appendix A.2.1), and play critical roles in regulation of gene expression, 
embryonic development and genomic stability.  
3.1 DNA METHYLATION 
DNA methylation is a crucial element in controlling gene expression, including genomic 
imprinting, X-inactivation and in maintaining the nuclear architecture of the cell.  Additionally, 
methylation of DNA helps prevent chromosomal instability and aberrant translocations and 
represses the expression of intragenomic viral elements [4, 119-121].  During early embryonic 
development, alternating waves of methylation and demethylation program cellular growth and 
differentiation [122].  DNA methylation patterns are established early in embryogenesis and are 
under tight control. 
DNA methylation occurs at dinucleotides in which cytosine is upstream and adjacent to 
guanine, called CpGs. This takes place when S-adenosylmethionine (SAM) donates a methyl 
(CH3) group that is covalently attached to the 5-carbon of a cytosine pyrimidine ring in a reaction 
catalyzed by the enzyme DNA methyltransferase (DNMT) [120, 123].  Approximately 50-70% 
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of CpG dinucleotides are methylated in normal human tissue, termed global methylation [124].  
However, most of the human genome is depleted of CpG dinucleotides due to the relative 
instability of m5C, which can result in spontaneous hydrolytic deamination of the cytosine base 
to thymine [120].  CpGs are not randomly distributed throughout the genome but rather are 
concentrated in CpG enriched regions [4, 120, 125] referred to as CpG islands.  Specifically, 
CpG islands are defined as a sequence greater than 0.5 kb with a G+C content greater than or 
equal to 55% and an observed:expected CpG ratio greater than 65% [126].  They typically range 
from 0.5 to 5 kb in length and occur on average every 100 kb in the genome [123].  These CpG 
islands are often disproportionately concentrated in the 5’ promoter regions of genes. 
Approximately 50% of all human genes have CpG islands in the promoter region [120, 123, 
125].  While CpG dinucleotides are frequently methylated in normal tissue, promoter-associated 
CpG islands are generally not methylated, although methylation of subgroups of CpG islands 
may occur [4, 120, 125].   
During DNA replication, the methylation pattern of the parent strand is transferred onto 
the new strand by DNMT1 [120].  DNMT1 has an affinity for hemimethylated DNA [127] and 
towards replication foci [128]. However, during early embryonic development or carcinogenesis, 
previously unmethylated DNA may be methylated in a process mediated by DNMT3a or 
DNMT3b, which is termed de novo methylation [120, 123].  DNMT3b has a propensity to target 
pericentromeric satellite regions for methylation, which are prone to loss of stability as a result of 
hypomethylation, leading to chromosomal breakage [129]. 
There are several mechanisms guarding against aberrant promoter methylation 
(hypermethylation), including active transcription, active demethylation, timing of replication 
and prevention of access to DNMT by local chromatin structure [123].  Enzymes that actively 
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demethylate DNA are called demethylases.  These may include the glycosylases thymine-DNA 
glycosylase (TDG) and methyl-CpG-binding domain protein 4 (MBD4), which remove the 
methylated cytosine (5-meC) leaving the deoxyribose intact to be replaced with a new cytosine 
via DNA repair [130, 131]; methyl-CpG-binding protein 2 (MBD2), which is believed to 
demethylate by hydrolyzing 5-meC to cytosine and methanol [123]; or thymine removal by 
glycosylases through the G/T mismatch base excision repair pathway following 5-meC 
deamination to thymine by DNMT3a or DNMT3b [131]. 
Generally, methylation of CpG islands in the promoter region is associated with 
transcriptional silencing of the gene, whereas methylation of downstream gene sequences has no 
influence on expression [120].  DNA methylation is capable of repressing gene expression in 
three general ways [123].  One mechanism is through direct interference with transcription 
factors.  Several transcription factors, including AP-2, c-Myc, CREB, E2F, and NFkB, recognize 
and bind promoter regions containing CpG islands and are inhibited by methylation.  A second 
mechanism involves inhibition of transcription through the direct binding of transcriptional 
repressors to 5-meC in the promoter region, including MBD1, MBD2, MBD4, Kaiso, MeCP1, 
and MeCP2.  Finally, CpG methylation can guide the deacetylation of histones and subsequently 
alter chromosome structure to prevent transcription.  Methylated cytosines of silenced promoters 
can bind methyl-CpG-binding-domain proteins (MBD), forming a complex involving histone 
deacetylase enzymes (HDAC) [120]. 
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3.2 EPIGENETIC INTERACTIONS 
            3.2.1 Epigenetics and Aging 
As people age, global methylation decreases and promoter methylation tends to increase [132].  
Loss of genomic imprinting [133] and reactivation of X-chromosome inactivated genes [134] 
over time has been observed in animal models.  Differential patterns of DNA methylation & 
histone modifications have been reported to occur even in monozygotic twins during the aging 
process.  Differences increase with age and are particularly evident among twins spending longer 
portions of their lifetimes apart, which suggest an environmental interaction with epigenetics 
[135]. 
            3.2.2 Epigenetics and Gender 
Gender may influence susceptibility to epigenetic alterations, although the mechanisms are not 
fully understood. Presently, there are mixed reports on the role of sex in DNA promoter 
methylation. Female gender has been positively associated with DNA methylation for some 
genes, including MTAP in gastric cancer [136], p14arf in colorectal cancer [137], and CDH1 in 
lung cancer tissue [138]; but protective for others, such as RASSF1A, TSLC1/IGSF4, and ESR1 
in lung cancer [138-140], and methylation latent trait in bladder cancer based on a 16 gene panel 
[141].  There is experimental evidence suggesting that risk of promoter methylation for certain 
genes varies in a tissue-specific, gender-dependent manner, as do the transcriptional targets, 
based on the effects of sex hormones on epigenetic states and differential distribution of sex 
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hormone receptors [142]. Additionally, female gender has been associated with lower levels of 
global methylation in blood [143].  
            3.2.3 Epigenetics and Environmental Exposures 
Environmental exposures can alter epigenetic regulation of the genome, although the precise 
mechanisms are largely unknown.  People are most susceptible to epigenetic dysregulation 
during prenatal and neonatal development, puberty and old age [144]. 
Tobacco smoke is known to exert its carcinogenicity via both genetic and epigenetic 
mechanisms.  Smoking has been associated with hypermethylation of several tumor suppressor 
genes in cancers of the lung, bladder, prostate and head and neck [139, 141, 145-147]; and 
specific associations of smoking dose and duration with promoter methylation of tumor 
suppressor genes have been reported [139, 145]. Promoter methylation of CDKN2A has been 
reported in the normal oral mucosa of 9.7% of cigarette smokers [148], supporting the notion 
that this can be an early event in SCCHN. An association of smoking and global DNA 
hypomethylation in SCCHN tissue has also been reported [149, 150].  Additionally, 
benzo(α)pyrene diol epoxide (BPDE), a chemical found in cigarette smoke, preferentially binds 
to guanines adjacent to methylated CpG dinucleotides, forming adducts that can induce G to T 
transversions [151, 152].   Similarly, acrolein, an aldehyde found in cigarette smoke, favors 
binding to 5-meC sites that can induce in C to T transitions [153].  Smoking can also affect 
epigenetics through inhibition of metabolism and storage of folate [79-81], which is the primary 
methyl source for the DNA methylation process, as previously discussed. 
Alcohol can affect DNA methylation through the reduction of available methyl groups by 
blocking folate absorption and through the inhibition of S-adenosylmethionine (SAM), 
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preventing methyl transfer [93]. Furthermore, acetaldehyde, the primary metabolite of ethanol, 
has been shown to inhibit DNMT activity in mice [102].  Consumption of alcohol has been 
associated with promoter methylation of Soluble Frizzled Receptor Protein 1 (SFRP1) [154], a 
gene involved in the WNT signaling pathway; and global hypomethylation [150].  
Other environmental exposures have been implicated in epigenetic alterations as well.  In 
experimental models, exposure to arsenic depletes s-adenosylmethionine (SAM), the primary 
methyl donor in DNA methylation, thus inducing global hypomethylation [155, 156]; but has 
also been associated with promoter hypermethylation of p53 [157] and RASSF1A [141].  
Ultraviolet radiation exposure has been reported to induce global hypomethylation [5], while 
ionizing radiation has been shown to induce hypermethylation of CDKN2A [158].  Nickel can 
actuate de novo methylation of tumor suppressor genes through induction of heterochromatin 
conformation by suppressing H4 acetylation [159, 160].   Chromium exposure can cause gene 
silencing via histone acetylation through interactions with HAT and HDAC enzymes [144].  
Other metals such as cadmium and zinc also can affect epigenetics, both which have been shown 
to inhibit DNMT activity [161, 162].  Additionally, HDAC inhibitors bind through zinc at zinc-
binding domains, preventing chromatin condensation [163].   
            3.2.4 Epigenetics and Diet 
Although much of the effect of diet on epigenetics is unknown, several dietary factors have been 
associated with altered epigenetic patterns in humans.  Among the most compelling are nutrients 
involved in one-carbon metabolism because they directly affect the supply of available methyl 
groups.  This includes nutrient cofactors such as vitamin B6, vitamin B12, and the riboflavin 
derivative, flavin adenine dinucleotide (FAD); as well as dietary methyl, including folate, 
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methionine, and choline [160].  In one-carbon metabolism, the intracellular form of folate, 5,10-
methylenetetrahydrofolate, is irreversibly converted to the predominant extracellular form, 5-
methyltetrahydrofolate, which acts as the primary methyl donor in the conversion of 
homocysteine to methionine.  Subsequently, methionine is converted to S-adenosylmethionine 
(SAM), which acts as the primary methyl donor in the DNA methylation process, catalyzed by 
DNMT [160].  Deficiencies in any of these nutrients could potentially result in an altered 
methylation process.  
There is experimental evidence that certain dietary factors, such as zinc [164] and 
selenium [157] deficiency, may induce global hypomethylation.  Conversely, other dietary 
factors, such as vitamin C deficiency, have been associated with local promoter 
hypermethylation [160].  Furthermore, there are some dietary factors that may result in both 
global hypomethylation and localized promoter hypermethylation: folate deficiency has been 
associated with increased global hypomethylation and cancer risk [160], and but also with 
hypermethylation of the 5’ promoter region of CDH13 (H-cadherin) [165]; and increased intake 
of retinoic acid has been associated with both as well [160].   
There are additional mechanisms through which diet can affect epigenetics.  Soy 
phytoestrogens have been associated with maintenance of a protective methylation pattern and 
may reduce the risk of certain cancers [160].  Phenols from green tea (epigallocatechin-3-gallate) 
are reported to affect methylation by binding and inhibiting DNMT, resulting in reactivation of 
methylation-silenced genes in cancer cell lines [166].  Additionally, dietary factors can act 
through histone modification.  Butyrate, a short-chain fatty acid, has been shown to promote 
hyperacetylation of histones associated with the RET proto-oncogene, opening the chromatin 
conformation and thus resulting in its upregulation [167]. 
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            3.2.5 Epigenetics and Viral Infection 
Although the mechanistic details are poorly understood, viruses may epigenetically alter host 
gene expression.  DNA methylation and chromosome modifications are known to be involved in 
regulation of viral gene expression [5].  However, viral-associated methylation is not specific for 
viral DNA but rather occurs throughout the host genome [168, 169].  Infection with human 
papillomavirus (HPV), Epstein-Barr virus (EBV), simian virus 40 (SV40), hepatitis B (HBV) 
and hepatitis C (HCV) are all associated with epigenetic modification of the host DNA. EBV has 
been associated with promoter methylation and silencing of several genes in gastric [170] and 
nasopharyngeal cancers [171]; HBV and HCV in hepatocellular carcinoma [172-176]; and SV40 
in mesothelioma [177, 178]. 
Likewise, HPV pathogenesis has been associated with altered CpG methylation and 
promoter methylation in cervical cancer [179-182], SCCHN [154] and in female non-smoking 
pulmonary adenocarcinoma patients [183]; although Dong and colleagues report an inverse 
relationship for HPV-16 and promoter methylation in SCCHN [184]. The E7 viral oncoprotein 
has been observed in vitro to directly associate with and stimulate DNMT1 activity [185], and 
DNMT1 expression is increased in low-grade cervical intraepithelial neoplasia (a premalignant 
condition) and further elevated in high-grade cervical neoplasia and invasive cervical cancer 
[186].   
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3.3 DNA METHYLATION AND CANCER 
Epigenetics play a major role in carcinogenesis.  Altered methylation patterns are common 
findings in cancer.  DNA methylation generally affects cancer development in 3 main ways: 
through global hypomethylation, promoter hypermethylation and induction of point mutations 
(futher discussed in Appendix A.2.2) [120].   
            3.3.1 Hypomethylation 
Cancer cells generally exhibit global hypomethylation [4, 120], with tumor cells losing between 
20%-60% of their genomic 5-methylcytosine relative to normal tissue [187].  Hypomethylation 
generally is an early event in head and neck carcinogenesis and increases as the tumor progresses 
[4, 188].  This can result in overexpression of oncogenes or oncogenic microRNAs and can 
allow the transcription of parasitic sequences integrated into the genome, such as viral DNA.  
However, the main carcinogenic effect of hypomethylation stems from loss of genomic stability, 
which increases the risk of chromosomal breaks, translocations or allelic loss [4, 120, 189].  This 
is particularly true for hypomethylation of pericentric chromosomal regions, characteristic of 
many cancers, and may further increase the probability of chromosomal breakage [120]. 
            3.3.2 Hypermethylation 
Cancer cells frequently exhibit localized methylation of promoter CpG islands 
(hypermethylation), which are generally unmethylated in normal tissue [4, 120].  Promoter 
methylation is associated with transcriptional silencing, is at least as common as DNA mutation 
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in the inactivation of tumor suppressor genes and is considered to be a major event in 
carcinogenesis.  There are approximately 100-400 hypermethylated CpG islands in the promoter 
regions of most tumors [4]. Some genes are hypermethylated in multiple cancers, such as 
RASSF1A and CDKN2A, while others are cancer-specific [123].  Hypermethylation can affect 
genes involved in cell cycle control, DNA repair, carcinogen metabolism, cell-cell interactions, 
apoptosis and angiogenesis [4, 160].  It occurs at different stages of cancer development in 
different genes and interacts with genetic lesions; and often begins in early stages, even in 
normal-appearing tissue preceding cancer, and then progressively increases during 
carcinogenesis [4, 125, 160].   
Patterns of hypermethylated tumor suppressor genes appear to be cancer-specific [190, 
191].  The systematic promoter methylation of multiple tumor suppressor genes within the same 
cancer type, known as CpG island methylator phenotype (CIMP), has been reported in several 
cancers, including colorectal, gastric, esophageal, pancreatic, esophageal, liver, ovarian, 
glioblastoma, acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML) 
[120].  Promoter methylation of MINT (Methylated In Tumor) loci has been proposed as an 
objective criterion for defining CIMP [192].  Tumor-specific methylation profiles have also been 
suggested for SCCHN, non-small cell lung cancer, bladder cancer and mesothelioma, but were 
not specific enough to consistently classify the tumors, with misclassification rates of 28%-32% 
[193]. Nonetheless, an association has been reported between MINT promoter methylation and 
methylation index (number of methylated tumor suppressor genes) in SCCHN [193]. 
Some CpG islands are located in chromosomal regions prone to large-scale epigenetic 
dysregulation [4].   Additionally, histone modifications can mark a gene for promoter 
methylation.  Methylation of promoter CpGs is associated with a specific combination of histone 
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markers: deacetylation of histones H3 and H4, loss of H3K4 trimethylation, gain of H3K9 
methylation, and gain of H3K27 trimethylation [194-198].   
3.4 METHYLATION AND SCCHN 
As with other solid tumors, aberrant promoter methylation is a common event in SCCHN.  It is 
among the earliest events in head and neck carcinogenesis, preceding alterations in protein 
expression levels [25].  Promoter methylation of CDKN2A and MGMT has been detected in 
leukoplakia, a premalignant lesion [199].  There are several genes commonly hypermethylated in 
SCCHN (Table 2), including genes known to function in pathways involving cell-cycle control, 
apoptosis, cell-cell adhesion, DNA repair and tumor invasion [21, 25, 26, 112, 154].   
 
Table 2. Genes commonly hypermethylated in SCCHN  
Gene Function 
APC cell cycle control; cell-cell adhesion; cell motility 
CDH1 (E-cadherin) cell-cell adhesion 
MGMT DNA repair 
CDKN2B (p15) cell cycle control 
CDKN2A (p16/p14) cell cycle control 
RARB transcription regulator; cell growth; differentiation 
ATM cell cycle control; DNA damage signaling 
DCC cell growth; apoptosis; differentiation 
DAPK apoptosis 
CCNA1 cell cycle control 
AIM1 cytokinesis 
PGP9.5 (UCH-L1) protein ubiquitylation 
Lhx6 differentiation 
RASSF1A cell cycle control; apoptosis 
ESR estrogen receptor 
HIC1 transcriptional repressor 
TIMP3 degradation of the extracellular matrix  
SFRP1,2,4,5 cell growth; cell-cell adhesion; morphogenesis 
 
Sources: [21, 25, 26, 112, 154] 
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As a result of its anatomic location, DNA from head and neck tumors may be shed into 
saliva, allowing for identification of genetic or epigenetic aberrations using oral rinse 
(mouthwash) samples.  Promoter methylation has been detected in oral rinses from patients with 
SCCHN and premalignant tumors [21, 23-26, 199].  Studies have reported variable correlation of 
promoter methylation by gene in oral rinse or saliva to tumor tissue with fair-to-good overall 
agreement [24-26].  However, it should be noted that the validation studies have thus far been 
relatively small and limited in scope. 
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4.0  MICRORNA 
4.1 BIOLOGY AND FUNCTION 
MicroRNAs (miRNA) are small, evolutionarily conserved, non-coding ribonucleic acid (RNA) 
molecules involved in regulation of gene expression in essentially all eukaryotic organisms.  
They are on average 22 nucleotides in length, ranging from 18-25 nucleotides [6, 200-203].   
MicroRNAs are a recent discovery, being first described in 1993 with the identification of Lin-4, 
a small RNA that was determined not to encode a protein but which repressed expression of Lin-
14 protein in the nematode C. elegans [204].  Presently, there are 695 human miRNA sequences 
catalogued in the miRNA registry (miRBase) [205, 206].  It is estimated that up to 30% of 
human genes are regulated by miRNA expression [207].  MicroRNAs are involved in control of 
crucial cellular functions, including proliferation, apoptosis, development, differentiation and 
metabolism [201].  They are tightly regulated and have been observed to show tissue-specific 
expression patterns during embryogenesis [200], though they are expressed in all tissues and at 
all stages of development [208]. 
            4.1.1 MicroRNA Transcription 
MicroRNA expression is regulated by transcription factors and transcribed by RNA Polymerase 
II (Pol II), similar to protein-coding genes, although the precise mechanisms of transcriptional 
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control of miRNAs are not entirely understood.  While most miRNAs reside within intergenic 
non-coding regions [209], they can also be located in introns or exons of coding genes [6].  
Many miRNAs are embedded close to other miRNAs in the genome, giving rise to miRNA 
clusters [209].  Single and clustered miRNAs can be transcribed from their own promoters, 
generally located within 500 base pairs of the 5’ end of the miRNA, as single or polycistron 
transcriptional units, respectively [208, 209].   
            4.1.2 MicroRNA-Mediated Gene Regulation 
Following transcription, the miRNA undergoes a maturation process, described in detail in 
Appendix A.3.1. The mature miRNA forms a complex with a member of the Argonaut (Ago) 
protein family, termed the RNA-induced silencing complex (RISC), and guides it specifically to 
the target messenger RNA (mRNA) through base pairing interactions generally at the 3’ UTR of 
the target.  Nucleotides 2-7 in the 5’ region of the miRNA, called the seed region, bind the target 
mRNA through near-perfect base-pairing [210].  The remainder of the miRNA binds the target 
mRNA with varying degrees of complementarity [210].  If the miRNA is a perfect or near-
perfect complement, cleavage and degradation of the mRNA is induced through de-capping of 
the 5’ m7G cap or de-adenylation of the poly(A) tail [6, 200-203].  If there is a partial 
complement, RISC inhibits translation [6, 200-203] through competitive m7G cap binding by 
Ago 2 with the translational initiating factor eIF4E [211]. These translationally-silenced mRNA-
RISC complexes remain in the cytoplasm and accumulate, forming processing bodies (P-bodies) 
[208].  P-bodies contain decapping proteins and exoribonuclease, and therefore are capable of 
degrading the mRNAs.  However, there is newly emerging evidence that miRNA translational 
silencing may be reversible, allowing mRNAs to leave P-bodies and migrate to ribosomes for 
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translation [212].  Since base pairing with the target does not have to be a perfect compliment, a 
single miRNA can potentially affect mRNA and protein levels of 200 or more genes [6, 203]. 
            4.1.3 Epigenetic Regulation of MicroRNA 
MicroRNA expression can be regulated epigenetically, either through DNA methylation [6] or 
histone modification [213].  Approximately 10% of miRNAs are regulated by DNA methylation 
[7] and are more frequently methylated than protein-coding genes [202].  Although it is currently 
unknown exactly why this is, three general reasons have been suggested [202]:  (1) the increased 
frequency of miRNA methylation could be due to the specific nucleotide sequences surrounding 
the miRNA-associated CpG islands;  (2) miRNA could be embedded in specific chromosomal 
structures predisposing them to methylation; (3) the predilection for methylation could be related 
to the tight regulation of miRNA expression.    
There are three general mechanisms by which miRNA expression can be controlled 
through methylation:  (1) most commonly, miRNA can be embedded within or near a CpG 
island, which functions as its promoter [6, 202]; (2) miRNAs can be located within an imprinted 
region [214, 215], thus preventing transcription; (3) intronic miRNAs can be regulated by CpG 
island methylation of the promoter of the host gene [216, 217].  Forty-seven percent of miRNAs 
in the miRNA registry database (miRBase), and all miRNAs currently linked to epigenetic 
regulation, are associated with CpG islands [202].  Some miRNA promoters are unmethylated in 
normal tissue, while others are normally methylated [6, 202, 203, 218].  Promoter methylation of 
miRNA results in reduced expression or transcriptional silencing. 
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4.2 MICRORNA AND CANCER 
The first evidence of the association between aberrant miRNA expression and cancer was the 
2002 study by Calin and colleagues reporting the down-regulation and frequent deletion of miR-
15a and miR-16-1 in chronic lymphocytic leukemia (CLL) [219].  Shortly after came the first 
description of altered miRNA expression in solid tumors, reporting down-regulation of miR-143 
and miR-145 in colorectal carcinoma [220].   
MicroRNAs are differentially expressed in cancers compared to normal tissue.  These 
differences are both tissue- and tumor-specific [201-203].  The majority of miRNAs are down-
regulated in cancer, however some are up-regulated [202]. Altered miRNA expression occurs 
early in carcinogenesis [208].  Abnormal miRNA expression has been identified in premalignant 
tumors, including colonic and pituitary adenomas [220, 221].  Additionally, miR-221 has been 
shown to be highly overexpressed in normal thyroid tissue adjacent to cancers, but not in normal 
thyroid tissue in patients without thyroid cancer [222]. 
MicroRNAs can function as either tumor suppressors or oncogenes (Table 3).  Those that 
target and regulate proto-oncogenes act as tumor suppressors, so when they are down-regulated 
or silenced, the target oncogene is overexpressed [201].  Conversely, miRNAs that target tumor 
suppressor genes can act as oncogenes when overexpressed [201].  Some miRNAs operate as 
both tumor suppressors and oncogenes, dependent upon the tumor type [223].  This may be due 
to the notion that since different miRNAs are involved with different cellular pathways in 
different tissues, the effect on processes such as proliferation, differentiation and apoptosis may 
vary by form of cancer [223]. 
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Table 3.  MicroRNAs with altered expression in multiple solid tumors  
 miRNA Function Cancer/Tumor Types 
let-7-a-2 Tumor suppressor Breast, lung, liver 
let-7-a-3 Tumor suppressor Breast, liver 
let-7d Tumor suppressor Breast, liver 
let-7f Tumor suppressor Breast, liver, thyroid 
miR-10b Tumor suppressor Breast, liver 
miR-15b Tumor suppressor Thyroid, pituitary adenoma 
miR-17-92 Oncogenic Lung, thyroid, liver, neuroblastoma 
miR-21 Oncogenic Breast, lung, thyroid, liver, ovary, pancreas, 
glioblastoma, head and neck 
miR-24-2 Oncogenic Lung, thyroid 
miR-34a Tumor suppressor Breast, bladder, prostate, pancreas, melanoma 
miR-101 Tumor suppressor Breast, lung, pituitary adenoma 
miR-102 Oncogenic Breast, thyroid 
miR-124a  Tumor suppressor Lung, liver, colon, medulloblastoma,  
pituitary adenoma 
miR-124a  Oncogenic Tongue  
miR-125a Tumor suppressor Breast, lung 
miR-125b-1  Tumor suppressor Breast, ovary 
miR-125b-1  Oncogenic Thyroid, glioblastoma 
miR-125b-2  Tumor suppressor Breast 
miR-125b-2  Oncogenic Thyroid, glioblastoma 
miR-127 Tumor suppressor Breast, lung, colon, pancreas, bladder, cervix 
miR-137 Tumor suppressor Oral, glioblastoma 
miR-140 Tumor suppressor Breast, lung, thyroid, ovary, pituitary adenoma 
miR-141 Tumor suppressor Liver, pituitary adenoma 
miR-142 Tumor suppressor Thyroid, liver 
miR-143 Tumor suppressor Breast, lung, liver, colon 
miR-145 Tumor suppressor Breast, lung, liver, colon, ovary 
miR-146 Oncogenic Lung, thyroid 
miR-150 Oncogenic Lung, pituitary adenoma 
miR-155 Oncogenic Breast, lung, thyroid, pancreas 
miR-181a  Tumor suppressor Liver 
miR-181a  Oncogenic Thyroid 
miR-181b Tumor suppressor Glioblastoma, pituitary adenoma 
miR-181c  Tumor suppressor Liver, glioblastoma 
miR-181c  Oncogenic Thyroid 
miR-191 Oncogenic Breast, lung, pituitary adenoma 
miR-192 Oncogenic Lung, pituitary adenoma 
miR-193a Tumor suppressor Oral, glioblastoma 
miR-198 Tumor suppressor Lung, glioblastoma 
miR-199b Tumor suppressor Lung, liver 
miR-202 Oncogenic Breast, thyroid 
miR-203 Oncogenic Breast, lung 
miR-210 Oncogenic Breast, lung 
miR-212 Oncogenic Lung, pituitary adenoma 
miR-213 Oncogenic Breast, thyroid 
miR-219-1 Tumor suppressor Lung, thyroid 
miR-220  Tumor suppressor Lung 
miR-220  Oncogenic Thyroid  
Sources: [17, 27, 200, 223-235] 
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            4.2.1 MicroRNA and Tumor Classification  
Profiling studies have identified multiple dysregulated miRNAs in cancer and have been able to 
classify cancer by type [236, 237]. These profiling studies report global down-regulation of 
miRNAs in cancer and have thus far been more tumor-specific compared with mRNA expression 
profiles, which tend to be more tissue-specific than tumor-specific [208].   
            4.2.2 MicroRNA and Prognosis 
The potential prognostic value of miRNAs is supported by their involvement in proliferation, 
differentiation and apoptotic pathways.  MicroRNA expression profiles have been correlated 
with clinical outcome [201-203].  Dysregulation of individual miRNAs have also been 
associated with prognosis. For example, downregulation of miR-106a is associated with 
decreased survival [11], and miR-320 and miR-428 with decreased disease-free survival [16] in 
colon cancer patients; and decreased expression of let-7 family members has been associated 
with poorer survival in lung cancer patients [18] and in SCCHN patients when downregulated in 
conjunction with miR-205 [10], although promoter methylation of let-7-3 has been associated 
with better prognosis in ovarian cancer [238].  Reduced expression of miR-205 is also an 
independent predictor of loco-regional recurrence of SCCHN [10].  Upregulation of miR-21 has 
been associated with poorer survival in breast [19, 239], pancreatic [12] and non-small cell lung 
cancers [15]; overexpression of miR-211 is associated with poor prognosis in oral squamous cell 
carcinoma [9]; overexpression of miR-16 is associated with decreased overall and disease-free 
survival in pediatric acute lymphocytic leukemia (ALL) patients [13]; upregulation of miR-210 
in breast cancer correlates with decreased survival [8]; and higher expression levels of miR-20b 
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and miR-150 are associated with decreased survival in patients with undifferentiated gastric 
cancer [14]. Altered miRNA levels have also been associated with tumor stage [11, 239], grade 
[19], lymph node metastasis [9, 14, 239] and vascular invasion [9, 11]. 
Low total levels of miRNAs correlate with poor differentiation [18, 237, 240].  In fact, 
miRNA profiles have been shown to better classify poorly differentiated tumors compared to 
mRNA profiles [241].  As further evidence, miRNA expression can be triggered through 
induction of cellular differentiation with all-trans retinoic acid [237].  
            4.2.3 MicroRNA and Metastasis 
Metastases are the primary cause of death for patients with solid tumors [187], and there is 
accumulating evidence that microRNAs play a role in these events.  Expression of miR-10b has 
been reported to be increased in metastatic breast cancer cells compared to non-metastatic cells 
[242].  Additionally, several metastasis-related genes are predicted miRNA targets, including 
Lysyl Oxidase (LOX), E-cadherin (CDH1), Integrin alphaVbeta-3, Syndecan-1 (SDC1), 
Mesenchymal-Epithelial Transition Factor (c-Met), Hypoxia-Inducible Factor-1α (HIF-1α), 
Tissue Inhibitor of Metalloproteinase-3 (TIMP-3), Adamalysin Metalloproteinase-17 (ADAM-
17), and Fusin (CXCR4) [200].  Furthermore, the angiogenesis inhibiting genes 
Thrombospondin-1 (Tsp-1) and Connective Tissue Growth Factor (CTGF) are downregulated 
during angiogenesis and are potential targets of the oncogenic miR-17-92 cluster [243]. 
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            4.2.4 Epigenetic Dysregulation of MicroRNA in Cancer 
Dysregulated expression in at least one type of cancer has been reported in 25.8% of known 
human miRNAs [244], suggesting that they may be one of the largest classes of gene regulators 
associated with cancer.  Dysregulation of miRNAs can lead to changes in expression of their 
target genes, such as up-regulation of oncogenes or silencing of tumor suppressor genes, 
resulting in cellular dysfunction and eventually cancer.  Further discussion will focus on 
epigenetic dysregulation of microRNAs; however, other mechanisms are discussed in more 
detail in the addendum (Appendix A.3.5). 
Approximately 10% of miRNAs are regulated through promoter methylation, as 
previously discussed in Section 4.1.3.  Hypermethylation can lead to reduced expression or 
silencing of tumor suppressor miRNAs, whereas hypomethylation can lead to activation of 
oncogenic miRNAs.  There have been several reports in the literature of associations between 
altered methylation status of miRNAs and various cancers (Table 4), including lung, colorectal, 
breast, ovarian, oral, bladder, pancreatic, gastric, cholangiocarcinoma and several hematopoietic 
cancers [17, 27, 216, 218, 229, 231, 238, 245-252]. 
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Table 4.  MicroRNAs with altered methylation status in human cancer  
miRNA 
Oncogenic or 
Tumor Suppressor Cancer Type(s) Reference 
let-7a-3 Oncogenic Lung, ovarian [218, 238] 
miR-1 Tumor Suppressor Hepatocellular [246] 
miR-9 Tumor Suppressor Breast, colorectal [248, 253] 
miR-34a Tumor Suppressor Breast, lung, colorectal, renal, bladder, 
pancreas, prostate, melanoma 
[229] 
miR-34b/34c Tumor Suppressor Colorectal [251] 
miR-124 Tumor Suppressor Breast, colorectal, lung, gastric, lymphoma, 
leukemia  
[249, 252] 
miR-127 Tumor Suppressor Bladder, colorectal [231, 253] 
miR-129 Tumor Suppressor Colorectal [253] 
miR-137 Tumor Suppressor Oral, gastric, colorectal [17, 27, 252] 
miR-193a Tumor Suppressor Oral, gastric [27, 252, 253] 
miR-203 Tumor Suppressor ALL, CML [245] 
miR-223 Tumor Suppressor AML [247] 
miR-342 Oncogenic Colorectal [216]  
miR-370 Oncogenic Cholangiocarcinoma [250] 
 
4.3 MICRORNA AND SCCHN 
Altered expression of miRNAs has been reported in SCCHN, although the degree of 
dysregulation varies by study.  A recent microarray analysis by Kozaki and colleagues evaluated 
expression levels in 148 miRNAs in oral squamous cell carcinomas (OSCC) compared with 
normal oral mucosa, reporting down-regulation (< 0.5-fold) in 36.5% (54/148) and up-regulation 
(> 1.5-fold) in 7.4% (11/148) of miRNAs [27].  Using a 2-fold expression threshold, Childs 
reported downregulation in 18.2% (43/236) and upregulation in 2.5% (6/236) of miRNAs in 
SCCHN [10].  In another miRNA microarray of squamous cell carcinomas of the tongue with 
matched normal tissue, Wong and colleagues identified 8.3% (13/156) down-regulated and 
15.4% (24/156) up-regulated miRNAs, using 3-fold expression level changes [234].  In contrast, 
a miRNA profiling study by Chang and colleagues found only 9 of about 300 miRNAs to be 
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differentially expressed in SCCHN compared to normal tissue, with 8 overexpressed and 1 
underexpressed [224].  Differences in expression thresholds used in each study may explain 
much of the variability, although some of the heterogeneity between studies may be attributable 
to variability by head and neck cancer site.  The study by Chang used a mix of primary SCCHN 
tumors and cell lines, whereas Kozaki used only OSCC cell-lines and Wong used only tongue 
SCC cell-lines, although Tran and colleagues found no significant difference between sites for 
miRNA expression in SCCHN [254].    
Additionally, tumor-specific miRNA signatures for SCCHN have been reported.  In a 
study by Jiang and colleagues, 5 out of 5 SCCHN cell lines produced unique miRNA signatures 
compared to other cancer cell lines [255]. 
To date, there have been a limited number of studies regarding miRNA expression in 
SCCHN.  However, the associations of several differentially expressed individual miRNAs with 
SCCHN have been validated, including both oncogenic and tumor suppressor miRNAs (Table 
5).  
 
Table 5.  MicroRNAs with altered expression associated with SCCHN, validated on primary tumor samples 
miRNA Site Function Reference 
miR-1 Oral, Pharynx, Larynx Tumor Suppressor [10] 
Let-7d Oral, Pharynx, Larynx Tumor Suppressor [10] 
miR-21 Oral, Pharynx, Larynx Oncogenic [10, 224] 
miR-133 Oral, Pharynx, Larynx Tumor Suppressor [10] 
miR-137 Oral Tumor Suppressor [27] 
miR-184 Tongue Oncogenic [234] 
miR-193a Oral Tumor Suppressor [27] 
miR-205 Oral, Pharynx, Larynx Tumor Suppressor [10] 
miR-211 Oral Tumor Suppressor [9] 
miR-494 Oral, Pharynx, Larynx Tumor Suppressor [224] 
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            4.3.1 Tumor Suppressor microRNAs and SCCHN 
Tumor suppressor miRNAs that are reported to be downregulated in SCCHN include miR-1, 
miR-133, miR-137 (OSCC), miR-193a (OSCC), miR-205, miR-211 (OSCC), miR-494 and let-
7d.  The exact targets and function of miR-1, miR-133, miR-205, miR-211 and miR-494 are 
presently unknown [224].  However, miR-494 is located on chromosome 14q32.31, which is a 
region that is commonly deleted in SCCHN [256].  Furthermore, loss of heterozygosity at 14q is 
associated with poor prognosis in SCCHN patients, with a 3-fold increased risk of death [256]. 
Similarly, miR-211 is located in intron 6 of the TRPM1 gene at 15q13-q14, which is a region 
frequently lost in cancers, including SCCHN [257, 258].   Let-7d is commonly underexpressed in 
tumors.  Confirmed targets of the let-7 family include the K-Ras oncogene [259] and HMGA2 
[260], overexpression of which is associated with poor prognosis and metastases in lung cancer 
[261].   It has been reported that let-7d expression is repressed by c-myc expression [262], an 
oncogene frequently overexpressed in SCCHN [10]. 
Promoter methylation and down-regulation of miR-193a and miR-137 have been reported 
in oral squamous cell carcinoma (OSCC) [27]. In a study of 11 primary OSCC tumors with 
matched normal oral tissue, miR-193a was found to be hypermethylated in 72.7% (8/11) of cases 
[27]. Its targets include the transcription factor E2F6; possibly PTK2/FAK, which is involved in 
cellular growth and signal transduction; and possibly MCL1, an anti-apoptotic member of the 
BCL-2 family [27].  Expression of miR-193a correlates with increased apoptotic activity.  
Similarly, in the same study miR-137 promoter methylation was detected in 63.6% (7/11) of 
primary OSCC tumors, which will be described in more detail in the subsequent section (Section 
4.4). 
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4.4 MICRORNA-137 
MicroRNA-137 (miR-137) is located on chromosome 1p21.3, is associated with a large CpG 
island [17, 27] and is downregulated in OSCC [27], colon cancer [263], and gliomas [17]. 
MicroRNA-137 has been reported to undergo promoter methylation in OSCC [27], which was 
correlated with decreased expression levels; colon cancer [253]; gastric cancer cell lines [252]; 
and is also likely hypermethylated in gliomas [17]. Targets of miR-137 include Cyclin-
dependent kinase 6 (Cdk6) and possibly the transcription factor E2F6 and NCOA2/TIF2, which 
plays a role in histone acetylation [27].   
Cdk6 is a proto-oncogene involved in cell cycle progression (Figure 4).  It shares 71% 
homology with Cdk4 [264], both of which are ubiquitously expressed and form a complex with 
Cyclin D1 to phosphorylate pRb, leading to its inactivation.  The function of pRb is to repress 
the transcription of genes required for progression from G1 phase to S phase by binding and 
repressing the E2F transcription factor [264, 265].  When pRb is inactivated, E2F is released and 
the cell can progress to S phase.  Transfection of miR-137 into cells lacking its expression results 
in decreased Cdk6 expression and cell cycle arrest at the G1-S checkpoint in OSCC [27] and 
glioma [17] cell lines.  In further support, anti-Cdk4/6 has been shown to inhibit pRb 
phosphorylation at Cdk4/6 specific sites, arrest tumor growth in G1 phase, and induce tumor 
regression in lung, breast, colon, glioblastoma, and prostate human tumor xenografts [266]. 
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Figure 4.  The role of miR-137 in cell cycle control  
 
In addition to its role in cell cycle progression, recent findings suggest that Cdk6 is 
involved in cellular differentiation [264].  In cultured neural stem cell tissue, miR-137 is 
upregulated during differentiation but is downregulated in high-grade gliomas [17].  
Furthermore, transfection of miR-137 and miR-124 (which also targets Cdk6) was shown to 
induce neuronal differentiation in glioblastoma multiforme stem cells [17]. 
Although they are homologues and have overlapping function in the phosphorylation of 
pRb, Cdk4 and Cdk6 may also have discrete functions [264].  Cdk6 is upregulated in OSCC [28-
30] and neuroblastomas [267] without change in Cdk4 expression.  In addition, overexpression 
of Cdk6 has been independently associated with poor prognosis in medulloblastoma patients 
[268].  
Promoter methylation and corresponding downregulation of miR-137 in OSCC suggests 
that it may play an important role as a tumor suppressor in head and neck tumorigenesis.  This is 
further substantiated by the reduced expression of miR-137 in other cancers, as well as the 
biologic function and overexpression of its target, Cdk6, in OSCC. 
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5.0  BACKGROUND SUMMARY 
Head and neck cancer accounts for a considerable amount of preventable morbidity and 
mortality, both in the US and worldwide. Squamous cell carcinoma (SCCHN) makes up the 
majority of these cancers, comprising approximately 93% of all cases [3].  The strongest risk 
factors for SCCHN are tobacco and alcohol use, which have a synergistic multiplicative effect 
when combined [20, 108].   
DNA methylation is an epigenetic event that is crucial in controlling gene expression.  
Aberrant promoter methylation is at least as common as mutations in tumor suppressor gene 
inactivation and therefore is considered to be a major event in carcinogenesis, including the 
development of SCCHN.  Alcohol and tobacco are environmental exposures, which may alter 
the epigenetic machinery, potentially affecting patterns of methylation. 
Within the past few years, dysregulated expression of miRNAs, small non-coding 
regulatory RNA molecules, has been associated with various cancers, including SCCHN, and 
with poor prognosis. MicroRNA expression profiles show more tumor-specificity than mRNA 
profiles, suggesting that alterations affecting miRNA transcription, such as promoter 
methylation, may be more specific for tumor type than those affecting protein-coding genes.  
Additionally, dysregulated expression of miRNAs has been reported to have prognostic 
implications. It is estimated that 10% of miRNAs are controlled by DNA methylation [7].  A 
recent publication reported promoter methylation and downregulation of miR-137 in oral 
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squamous cell carcinoma (OSCC) [27].  Additionally, they found that miR-137 directly targets 
Cdk6, a key protein in cell cycle progression, and that downregulation of miR-137 results in 
increased cellular proliferation.  
Early diagnosis of SCCHN is crucial in treatment of the disease, resulting in a better 
prognosis for the patient.  Presently, visual inspection is the only proven screening method 
regularly used in clinical settings. Collection of oral rinse (mouthwash) samples is a simple, non-
invasive method for obtaining DNA from the upper aerodigestive tract epithelium [269, 270]. 
Promoter methylation of tumor suppressors can be early events in carcinogenesis that are 
detectable in oral rinse samples [21-25] and have potential value as biomarkers of SCCHN. 
Exploration of new biomarkers, such as miR-137 promoter methylation, will help aid in the 
search for better diagnostic and prognostic tools for early detection and treatment of SCCHN. 
The main objective of this proposed research is to contribute to our understanding of head 
and neck cancer by evaluating promoter methylation of miR-137 as a biomarker of SCCHN.  
Specifically, the 3 aims of this research, each corresponding to the subsequent 3 sections, are as 
follows: 
 
1a)   Evaluation of miR-137 promoter methylation as a diagnostic biomarker of 
SCCHN using oral rinse as a non-invasive DNA collection media 
1b)  Assess potential associations between smoking, alcohol consumption and other 
personal and behavioral risk factors for miR-137 promoter methylation in oral 
rinses from SCCHN patients 
2) Evaluate miR-137 promoter methylation in SCCHN tumor tissue as a prognostic 
biomarker 
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3) Determine the predictive value of oral rinse for identifying miR-137 promoter 
methylation in SCCHN using methylation-specific PCR 
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          6.0  MICRORNA-137 PROMOTER METHYLATION IN ORAL RINSES FROM 
PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK 
Langevin SM, Stone RA, Bunker CH, Grandis JR, Sobol RW, Taioli E. MicroRNA-137 promoter methylation in 
oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body 
mass. Carcinogenesis; 2010 Mar:[Epub Ahead of Print]. 
6.1   ABSTRACT 
Head and neck cancer represents 3.3% of all new malignancies and 2.0% of cancer-deaths in the 
US, the majority of which are squamous in origin. The overall 5-year survival is 60% and 
worsens with increasing stage at diagnosis. Thus, novel biomarkers for early detection of 
squamous cell carcinoma of the head and neck (SCCHN) are needed.  MicroRNA-137 (miR-
137) plays a role in cell cycle control and seems to undergo promoter methylation in oral 
squamous cell carcinoma tissue.  The main objectives of this study were to ascertain whether 
miR-137 promoter methylation is detectable in oral rinse samples, assess its association with 
SCCHN and identify potential risk factors for its occurrence. Oral rinse samples were collected 
from 99 SCCHN patients with no prior history of cancer and 99 cancer-free controls, frequency-
matched on gender; tumor tissue for 64 patients was also tested. Methylation of the miR-137 
promoter, assessed using methylation-specific PCR, was detected in 21.2% oral rinses from 
SCCHN patients and 3.0% from controls (OR = 4.80, 95% CI: 1.23-18.82).  Among cases, 
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promoter methylation of miR-137 was associated with female gender (OR = 5.30, 95% CI: 1.20-
23.44) and inversely associated with body mass index (OR = 0.88, 95% CI: 0.77-0.99). Promoter 
methylation of miR-137 appears to be a relatively frequently detected event in oral rinse of 
SCCHN patients, and may have future utility as a biomarker in DNA methylation panels.  The 
observed associations with gender and BMI help to shed light on potential risk factors for an 
altered methylation state in SCCHN. 
6.2 INTRODUCTION 
In 2008, head and neck cancer accounted for an estimated 47,560 new cases in the United States, 
representing 3.3% of all malignancies and 11,260 deaths [271].  The majority of these (93%) are 
squamous cell carcinoma of the head and neck (SCCHN) [3].  Use of tobacco and alcohol are 
each independently causally associated with development of this disease, and when combined 
have a synergistic multiplicative effect [20, 72]. The 5-year survival in SCCHN (approximately 
60%) has remained essentially unchanged over the past 3 decades despite therapeutic advances 
[20].  The majority of patients present with advanced stage disease (stage III or IV) [20],  and 
survival drastically declines with increasing stage at diagnosis.  There is therefore a need to 
assess novel biomarkers that could aid in the early detection of SCCHN. 
DNA promoter methylation, also known as hypermethylation, is an epigenetic change 
that often occurs as an early event in carcinogenesis [4], resulting in reduced or lost expression 
of the methylated gene.  Aberrant promoter methylation is considered to be at least as common 
as DNA mutation in the inactivation of tumor suppressor genes.  Altered microRNA expression 
 49 
also often manifests early in carcinogenesis [208].  An estimated 10% of microRNAs are 
regulated epigenetically through DNA methylation [7].    
MicroRNA-137 (miR-137) is associated with a large CpG island and has been reported to 
undergo promoter methylation in oral squamous cell carcinoma (OSCC) [27], gastric cancer cell 
lines [272] and colon cancer [253]. Prior evidence suggests that promoter methylation correlates 
with down-regulation of miR-137 in OSCC relative to non-cancerous oral tissue [27].  
MicroRNA-137 appears to play a role in cellular differentiation and cell cycle control, at least in 
part through negative regulation of Cdk6 expression, [17, 27].  It is hypothesized that over-
expression of Cdk6 may result in accelerated progression through the G1/S-phase checkpoint of 
the cell cycle, thus leading to increased proliferation and reduction in DNA repair capacity [273]. 
Oral rinse is a simple, non-invasive mode of DNA collection from the upper 
aerodigestive tract, and can be used to detect promoter methylation for SCCHN [21, 23-26].  The 
goal of this study was to evaluate miR-137 promoter methylation as a potential biomarker of 
SCCHN with a case-control design using oral rinse samples as a non-invasive, non-differential 
mode of DNA collection from case and control subjects.  Additionally, this study sought to 
investigate the association of miR-137 promoter methylation with smoking, alcohol consumption 
and other potential risk factors for SCCHN. 
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6.3 MATERIALS AND METHODS 
            6.3.1 Study Population 
This study was conducted as part of an epidemiology study in the University of Pittsburgh Head 
and Neck Specialized Program of Research Excellence (SPORE).  Subjects included 99 
consecutive adult patients (> 18 years of age) with primary squamous cell carcinoma of the oral 
cavity, pharynx, or larynx, diagnosed at the University of Pittsburgh Medical Center (Pittsburgh, 
PA) between September 2007 and April 2009, with no prior history of cancer; and 99 control 
subjects, frequency-matched on gender.  Control subjects were randomly selected from a pool of 
cancer-free patients with no prior history of malignancy seeking treatment at the University of 
Pittsburgh Department of Otolaryngology during the same time frame.  IRB approval was 
obtained under the University of Pittsburgh Head and Neck Cancer SPORE for sample collection 
and use of patient data.  All subjects provided written informed consent for participation in this 
study. 
            6.3.2 Data Sources 
Study subjects completed an epidemiologic questionnaire providing detailed demographic, 
personal and family cancer history, and behavioral risk factor information.  Clinical data from 
the cancer patients was collected at the time of diagnosis and entered into the University of 
Pittsburgh Head and Neck Oncology Registry. 
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            6.3.3 Oral Rinse Samples 
All subjects provided an oral rinse sample, obtained by swishing with 20 ml of saline for 20-30 
seconds.  Approximately 10 ml of commercial mouthwash (Scope) was added as a DNA 
preservative, and the samples were subsequently frozen at -20°C until DNA was extracted.  All 
samples (n = 99) from the head and neck cancer patients were collected prior to treatment. DNA 
was isolated and analyzed for miR-137 promoter methylation as indicated below. 
           6.3.4 Tumor Samples 
For 64 of the 99 cases (64.6%), archival formalin-fixed paraffin embedded (FFPE) tumor tissue 
resected prior to initiation of radiation or chemotherapy was obtained. This subset of paired 
samples was representative of the overall sample of head and neck cancer patients included in 
the original study, with an average age of 59.7 years (p = 0.92 vs age in total cases); the 
proportion of females was 23.4% (p = 0.71 vs female in total cases); and the distribution of site 
was 39.1% oral cavity, 34.4% pharynx and 26.6% larynx (p = 0.94 vs total cancer cases). DNA 
was isolated and analyzed for miR-137 promoter methylation as indicated below. Methylation of 
the miR-137 promoter in the DNA isolated from tissue samples was then compared to miR-137 
promoter methylation in the DNA isolated from oral rinse samples. 
            6.3.5 Methylation-Specific PCR 
DNA was extracted from buccal cells in oral rinse samples using the Puregene DNA 
Purification Kit (Gentra Systems, Minneapolis, MN) and from the FFPE tumor tissue using the 
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DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA).  DNA concentrations were quantified 
with the NanoDrop 1000 Spectrophotometer (ThermoFisher Scientific, Waltham, MA), and 
sodium bisulfite treatment was performed using the EZ DNA Methylation Kit (Zymo Research, 
Orange, CA).  
Methylation-specific PCR (MSP) was employed for the analysis of miR-137 promoter 
methylation, and the PCR products were then analyzed by separation on high-resolution 4% 
agarose E-Gels (Invitrogen, Carlsbad, CA). The primer set was designed using Methyl Primer 
Express software v 1.0 (Applied Biosystems, Foster City, CA), and primer sites were checked 
for genetic polymorphisms using the Enable Genome Browser [60].  The primer sequences used 
to assess miR-137 promoter methylation were as follows: methylated alleles: 
GCGGTAGTAGTAGCGGTAGC and ACCCGTCACCGAAAAAAA with an annealing 
temperature of 58°C and expected amplicon of 86 bp; and unmethylated alleles: 
GGTGGTAGTAGTAGTGGTAGT and TACCCATCACCAAAAAAAA with an annealing 
temperature of 51°C and expected amplicon of 86 bp.  As a quality control check, each PCR 
reaction included fully methylated and unmethylated bisulfite converted human DNA (Qiagen, 
Valencia, CA) as positive and negative controls.  Samples yielding faint positive signals were 
repeated twice more and only consistently positive samples were considered to be methylated. 
            6.3.6 Statistical Analysis 
Descriptive statistics of the study population were generated separately by case-control status 
and by miR-137 promoter methylation status.  Categorical variables were compared using 
Fisher’s exact test.  The Skewness-Kurtosis test [274] was used to determine if continuous 
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variables were normally distributed. The Mann-Whitney U test was used to compare non-
normally distributed continuous variables; otherwise a two-sample t-test was used.   The 
sensitivity, specificity and positive and negative predictive value of miR-137 promoter 
methylation for distinguishing patients with SCCHN from those with non-cancerous ENT 
conditions was calculated. This was performed overall for SCCHN and then by anatomic site. 
Multivariable logistic regression modeling was used to estimate the association between 
miR-137 promoter methylation and SCCHN.  A forward stepwise selection approach was 
employed to identify the preliminary main effects model, comparing the log likelihood of each 
model (PE = 0.15; PR = 0.20) [275].  All variables with P < 0.25 in univariate analysis were 
considered for the model.  All biologically plausible interactions were evaluated, and considered 
further if P < 0.15.  Functional form of the continuous variables was assessed using fractional 
polynomials [276], and any polynomial term providing a significant improvement over the linear 
term at P <  0.10 was considered. Global fit of the model was assessed using the Hosmer and 
Lemeshow goodness-of-fit test [277]; lack of fit was considered significant if P < 0.10.  
Subsequent subgroup analyses were performed restricted to the cases of a specific tumor site 
(oral cavity, pharynx, or larynx) compared to all controls. 
A second multivariable logistic regression model restricted to SCCHN patients was 
developed to identify potential risk factors for miR-137 promoter methylation.  A modified 
forward stepwise model selection approach was employed (PE = 0.15; PR = 0.20), starting with 
smoking duration and alcohol dose already in the model.  Otherwise, model checks were similar 
to those in the first model.  An interaction term for smoking and alcohol consumption was tested, 
considered for the model at P < 0.15. To account for the right skewness in smoking duration due 
to never-smokers (0 years) when modeled continuously, a binary ever/never smoking term was 
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included in the model and considered additively with smoking duration (y = β1*XEver/Never + 
β2*XYearsSmoking), where never-smoking = 0 and ever-smoking = 1 [278]. 
Two additional models were created using the same methodology described above, 
including fruit and vegetable consumption and stage at diagnosis, respectively, to generate 
adjusted estimates for these covariates.  Fruit and vegetable consumption was modeled 
continuously as log average daily servings of fruits and vegetables; and stage at diagnosis was 
modeled dichotomously as local (AJCC stage grouping I or II) or advanced (stage III or IV). 
Sensitivity and specificity was calculated for the ability of oral rinse to detect miR-137 
promoter methylation in tumor tissue.  Crude and multivariate logistic regression models were 
created restricted to the subgroup with FFPE data to assess gender specific methylation patterns.  
6.4 RESULTS 
            6.4.1 Association of miR-137 Promoter Methylation with Case-Control Status 
A description of the case-control study population is presented in Table 6.  SCCHN patients were 
significantly less educated relative to control subjects (P < 0.001), reported eating fewer servings 
of fruits and vegetables per day (P < 0.001) and had a lower median body mass index (BMI; P  = 
0.07).   Cases were more likely than controls to report as ever-smokers (P < 0.001) and among 
the ever-smokers, cases had a longer median smoking duration (P < 0.001).  Although there was 
no difference by case-control status in those identifying as ever-drinkers, cases reported longer 
median years of alcohol use (P = 0.003) and consumed more drinks per day on average (P < 
0.001).  Cases were also more likely to wear dentures (P < 0.001).  With respect to tumor site for 
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the SCCHN patients, 37.4% (n = 37) had tumors originating in the oral cavity, 37.4% (n = 37) in 
the oropharynx and 25.3% (n = 25) in the larynx. 
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Table 6.  Description of the study population by case-control status 
 
a Mann-Whitney U test 
b Fisher’s exact test 
c Estimated for 1-year prior to study enrollment based on patient reported weight at that time 
d 1 drink is considered to be 1 beer (12 oz), 1 glass of wine (5 oz) or 1 shot of liquor (1.5 oz) 
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MicroRNA-137 promoter methylation was detected in 21/99 (21.2%) of oral rinses from 
SCCHN patients and 3/99 (3.0%) from cancer-free control subjects. The final multivariate model 
for the association of miR-137 promoter methylation is presented in Table 7.  SCCHN patients 
had nearly 5-times the odds of having miR-137 promoter methylation relative to normal oral 
mucosa of cancer-free control subjects, adjusting for smoking duration, alcohol intensity, daily 
servings of fruits and vegetables and education level (OR = 4.80, 95% CI: 1.23-18.82). 
 
Table 7.  Association of miR-137 promoter methylation and SCCHN 
 
a Adjusted for total years smoking, average alcoholic drinks per day, education and daily servings of fruits and 
vegetables 
 
The sensitivity of miR-137 promoter methylation in differentiating patients with SCCHN 
from those with non-neoplastic ENT conditions was 21.2%, and the specificity was 97.0%.  The 
positive predictive value (PPV) was 87.5%, and the negative predictive value (NPV) was 55.2%.  
When considering anatomic site of tumor origin (Table 7), miR-137 promoter 
methylation was detected in 14/37 (37.8%) of oral rinse samples from patients with SCCHN of 
the oral cavity, 5/37 (13.5%) with pharyngeal tumors and 2/25 (8.0%) of laryngeal tumors.  The 
odds of oral cancer patients having miR-137 promoter methylation were more than 12-times as 
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high as cancer-free control subjects (OR = 12.18, 95% CI: 2.63-56.36); estimates were not 
statistically significant for pharyngeal (OR = 3.76, 95% CI: 0.68-20.76) or laryngeal cancer 
patients (OR = 1.33, 95% CI: 0.12-14.93).   
The PPV of miR-137 promoter methylation was 82.4% and the NPV was 80.7% for 
tumors of the oral cavity; PPV was 62.5% and NPV was 75.0% for pharyngeal tumors and PPV 
was 40.0% and NPV was 80.7% for laryngeal tumors. 
            6.4.2 Evaluation of Potential Risk Factors for miR-137 Promoter Methylation 
Univariate associations between miR-137 promoter methylation and various risk factors are 
summarized in Table 8 by case-control status.  While none of the factors considered were 
significantly associated with miR-137 methylation status in oral rinse in controls, among cases 
age (P = 0.02), female gender (P = 0.007), denture use (P = 0.01) and total years smoking (P = 
0.01) and drinking (P = 0.05) were positively associated with miR-137 promoter methylation; 
while body mass index (P = 0.002) was inversely associated.  None of the methylation-positive 
cases or controls reported being both never-smokers and never-drinkers. 
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Table 8.  Demographic and exposure variables by methylation status 
 
a Mann-Whitney U test 
b Fisher’s exact test 
c Two-sample t-test 
d Estimated for 1-year prior to study enrollment based on patient reported weight at that time 
 
 
A multivariable case-case comparison was performed (Table 9); covariates included in 
the final multivariate model were smoking duration, alcohol intensity, body mass index (BMI), 
denture use and gender. Women SCCHN cases had 5-times the odds of having miR-137 
promoter methylation (OR = 5.30, 95% CI: 1.20-23.44), and an inverse association of miR-137 
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promoter methylation with BMI per kg/m2 unit increase was observed (OR = 0.88, 95% CI: 
0.77-0.99).  There was a borderline association with wearing dentures and miR-137 promoter 
methylation (OR = 3.36, 95% CI: 0.91-12.36).  Although there was no significant association 
with total years of smoking there was a borderline positive trend (P = 0.09). There was no 
significant interaction between alcohol consumption and smoking.  Methylation in tumor tissue 
was 33.3% in females, and 12.2% in males, yielding a crude OR of 4.48 (95% CI: 1.26-15.90) 
and an adjusted OR of 12.29 (95% CI: 1.69-89.52) for the association between female gender 
and miR-137 promoter methylation in SCCHN tissue. Sensitivity of the oral rinse for detection of 
miR-137 methylation in tumor tissue was 45.5% and specificity was 81.1%.    
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Table 9.  Case-only analysis for the association of various risk factors with miR-137 promoter methylation 
 
a Adjusted for BMI, dentures, alcohol use and total years smoking 
b Adjusted for gender, dentures, alcohol use and total years smoking 
c Adjusted for gender, BMI, alcohol use and total years smoking 
d Adjusted for gender, BMI, dentures and total years smoking 
e Adjusted for gender, BMI, dentures and alcohol use 
f Adjusted for gender, BMI, dentures, alcohol use and total years smoking 
g Modeled continuously with an additive binary (ever/never) term as (y = β1*XEver/Never + β2*XYearsSmoking), where 
never-smoking = 0 and ever-smoking = 1 to account for right skewness due to never smokers 
 
Following the identification of a strong association between female gender and miR-137 
promoter methylation, post-hoc analysis revealed no significant difference in tumor site 
distribution for miR-137 promoter methylation by gender (P > 0.99). 
 62 
6.5 DISCUSSION 
Since 2006, numerous microRNAs have been reported to be hypermethylated in various cancer 
types [17, 27, 216, 218, 229, 231, 238, 245-251, 253, 272].  MicroRNA-137 is a tumor 
suppressor that targets Cdk6, an oncogene involved in progression past the G1/S-phase 
checkpoint, the loss of which has been shown to increase cellular proliferation in vitro [17, 27], 
and is possibly involved in cellular differentiation [17]. Therefore its transcriptional repression 
via DNA promoter methylation could have consequences with respect to carcinogenesis.  Recent 
studies have identified miR-137 promoter methylation in several types of solid tumors [27, 253, 
272], including oral squamous cell carcinoma [27]. In the present study, we have observed 
promoter methylation of miR-137 in 21.2% of oral rinse samples taken from SCCHN patients, a 
significantly higher proportion than observed in oral rinse samples from controls.  At present, 
this is the only study of miR-137 methylation status to include patients with cancers of the 
pharynx and larynx and, although others have detected promoter methylation in oral rinse 
samples, this marks the first time that microRNA promoter methylation has been evaluated as a 
biomarker of SCCHN using an oral rinse collection method.  
The proportion of samples exhibiting miR-137 promoter methylation was particularly 
high among patients with cancers of the oral cavity (37.8%), and lower for pharyngeal (13.5%) 
and laryngeal (8.0%) cancers.  This discrepancy by cancer site could be a result of local 
variations in quantity and quality of exposure to carcinogens, with the oral cavity more likely to 
be directly and highly exposed to alcohol and tobacco than the pharynx and larynx. Differences 
in cancer biology and/or sample collection method could also contribute to the observed 
differences.  The frequency of promoter methylation among cancers of the oral cavity is 
somewhat lower than that found in a small study conducted by Kozaki and colleagues [27], 
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where  promoter methylation was observed in 7/11 (63.6%) tumor tissue from patients with oral 
squamous cell carcinoma. In the subset of our patients where tissue from oral cavity cancers was 
available, we still observed a methylation frequency of 16%. Differences between our results and 
that of the Kozaki study could be due to random chance (P = 0.13 for comparison of frequencies 
between our study and the Kozaki study using a 2-sample test of proportions) or to variations in 
study populations resulting in genetic, behavioral and exposure diversity leading to differences in 
frequencies of miR-137 methylation. The present study includes predominately Caucasian 
American subjects, compared to the Japanese population included in the Kozaki study.  Another 
possible reason for the inter-study variation could be due to the study design and laboratory 
methods; the present study used MSP analysis of DNA isolated from formalin-fixed paraffin 
embedded (FFPE) tumor tissue, whereas Kozaki employed combined bisulfite restriction 
analysis (COBRA) [279] on DNA from fresh-frozen tissue. 
We observed miR-137 promoter methylation in 3.0% of oral rinse samples from cancer-
free subjects.  Others have reported hypermethylation of other genes in benign upper 
aerodigestive tract mucosa [148, 280, 281], including CDKN2A, a tumor suppressor gene also 
involved control of the G1/S-phase checkpoint, in oral tissue of smokers [148, 281].  MicroRNA-
137 promoter methylation has also been reported in “normal” adjacent colonic tissue of 
colorectal cancer patients [253].  This is the first report to evaluate miR-137 promoter 
methylation status in cancer-free subjects and to identify methylation status in benign mucosa of 
the upper aerodigestive tract. 
 Although a small sample-size, all 3 methylation-positive control subjects were identified 
as an ever-user of either tobacco, alcohol or both.  This supports the notion that environmental 
exposures may play a role in miR-137 hypermethylation in non-cancerous tissue.  These 
 64 
epigenetic field defects could potentially predispose such individuals to SCCHN, and therefore 
the relationship between smoking, drinking and miR-137 promoter methylation in upper 
aerodigestive tract mucosa of cancer-free individuals should be examined further in future 
studies with larger sample sizes. 
Using detailed information regarding smoking and drinking history, as well as other 
demographic and behavioral exposures, we were able to examine potential risk factors associated 
with miR-137 promoter methylation among SCCHN patients. The most striking finding in this 
regard is the observed increase in risk for miR-137 promoter methylation among women. The 
result was confirmed by the assessment of methylation in tumor tissue, thus making the 
possibility of a gender bias in oral rinse collection unlikely.  Presently, there are mixed reports on 
the role of sex in DNA promoter methylation. Female gender has been positively associated with 
DNA methylation for some genes, including MTAP in gastric cancer [136], p14arf in colorectal 
cancer [137] and CDH1 in lung cancer tissue [138]; but protective for others, such as RASSF1A, 
TSLC1/IGSF4 and ESR1 in lung cancer [138-140] and methylation latent trait in bladder cancer 
based on a 16 gene panel [141].  Experimental evidence suggests that risk of hypermethylation 
for certain genes may vary in a tissue-specific, gender-dependent manor, as do the transcriptional 
targets, based on the effects of sex hormones on epigenetic states and differential distribution of 
sex hormone receptors [142].  In experimental models, murine studies have demonstrated higher 
frequencies of methylation of certain genes following estrogen administration [282, 283]. In 
transgenic breast cancer mouse models, estrogen increases epigenetic inactivation of genes 
involved in cell cycle control and apoptosis with a dose-response effect [284].  Previous studies 
on sex hormone receptor distribution in SCCHN report that 51-79% of tumors are estrogen 
receptor positive and 42-49% are progesterone receptor positive [285, 286], with no apparent 
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variation by site.  Post-hoc analysis of our SCCHN study subjects reveals no significant 
difference in tumor site distribution for miR-137 promoter methylation by gender. 
We also observed an inverse association of BMI with miR-137 methylation status in 
cases, although there is presently little to no support for this in the literature. This relationship 
warrants further examination in future studies to identify the role of BMI in miR-137 promoter 
methylation and whether such an effect generalizes to aberrant promoter methylation of other 
genes. 
Recent work in the literature has begun to focus on epigenetic-environment interactions, 
particularly with regard to DNA methylation.  Here we report a borderline positive linear trend 
between smoking duration and miR-137 promoter methylation.  Although the environmental risk 
factors for promoter methylation and their corresponding mechanisms are poorly understood at 
present, several studies have reported an association between promoter methylation and cigarette 
smoking in lung [138, 139, 146], prostate [287] and bladder cancer tissue [147].  Others have 
also found similar dose-response relationships between smoking and promoter methylation [139, 
280, 287]. This suggests that one mechanism through which chronic cigarette smoking 
contributes to development of head and neck cancer is through stimulation of aberrant promoter 
methylation of tumor suppressor genes, possibly including miR-137. Although there were no 
significant associations of miR-137 promoter methylation with smoking or alcohol, the moderate 
sample size of this study limits our power to identify small effects. Rather, our finding of a 
borderline dose-response trend adds support, albeit mild, to the growing body of evidence that 
smoking is capable of inducing epigenetic alterations in addition to somatic mutations and 
chromosomal breaks.  At present, no other study has evaluated the effects of environmental 
exposures specifically on microRNA promoter methylation. 
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Also worthy of further discussion is the borderline association with wearing dentures. 
Although studies have found no apparent relationship between general denture use and oral 
cancer [288, 289], wearing of poorly fit or malfunctioning dentures has recently been associated 
with oral and pharyngeal cancer [290].  Improperly fitting dentures can result in chronic irritation 
of the surrounding mucosa. Halogenated pyrimidines that stem from damage caused by reactive 
oxygen species (ROS) as a result of the chronic inflammatory process mimic 5-methylcytosine 
and have been shown to stimulate DNMT1-mediated CpG methylation [291, 292], suggesting a 
potential role of inflammation in the induction of aberrant promoter methylation.  Further inquiry 
into the association with promoter hypermethylation in oral mucosa is required to elucidate the 
role, if any, of denture use. 
Strengths of this study include the high quality data collection and exposure details, 
which allowed us to carefully examine the relationship between potential environmental 
exposures and miR-137 promoter methylation.  Complete data eliminated some potential biases, 
while the detailed exposure data was conducive for quantitative assessment of smoking and 
drinking duration and intensity.  The use of oral rinse as a collection media allowed for non-
differential sample ascertainment from SCCHN patients and cancer-free control subjects, 
reducing the possibility of sample collection bias.  However, statistical power may be an issue 
due to the moderate sample size of this study. It is therefore conceivable that the null findings of 
associations with alcohol and tobacco exposures are due to a lack of power rather than a true lack 
of effect.  It is also possible that this study understates the prevalence of miR-137 promoter 
methylation as a result of misclassification bias stemming from the collection method, due to 
differential contact of tumor cells with the oral rinse media among cases.  This may be 
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particularly evident in smaller tumors or tumors that are not in or adjacent to the oral cavity, such 
as some pharyngeal and most laryngeal tumors.  
 Overall, the results of this study suggest that promoter methylation of miR-137 is a 
relatively common event in SCCHN.  Although it has a low sensitivity (21.2%), miR-137 
promoter methylation may have utility as a biomarker in DNA methylation panels, particularly 
given the good specificity (97.0%) and its presence in early stage tumors. Additionally, we have 
shed some light on environmental and personal risk factors associated with aberrant methylation 
of miR-137, particularly female gender.  Due to the involvement of miR-137 in cell cycle control 
and differentiation pathways, subsequent studies should further evaluate promoter methylation as 
a prognostic biomarker of SCCHN.  Also, future avenues of research should be aimed at 
correlation of miR-137 promoter methylation in oral rinse with tissue samples, overall and by 
specific tumor site, and at quantitative assessment of miR-137 promoter methylation in tumor 
tissue, with the final aim of developing etiologic and prognostic markers that could be used on 
large populations in a public health setting. 
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     7.0  EVALUATION OF MIR-137 PROMOTER METHYLATION AS A PROGNOSTIC 
BIOMARKER FOR SCCHN 
7.1 ABSTRACT 
The overall 5-year survival rate of approximately 60% for head and neck cancer patients has 
remained essentially unchanged over the past 30 years.  MicroRNA-137 (miR-137) plays an 
essential role in cell cycle control at the G1/S phase checkpoint. However, aberrant miR-137 
promoter methylation observed in squamous cell carcinoma of the head and neck (SCCHN) 
suggests a tumor-specific molecular defect that may contribute to disease progression.  The goal 
of this study is to assess, in formalin-fixed paraffin-embedded tumor tissue, the association 
between miR-137 promoter methylation and survival (both overall and disease-free) and with 
prognostic factors including stage, tumor size, nodal positivity, tumor grade and surgical tumor 
margin positivity.  Promoter methylation status of miR-137 was ascertained by methylation-
specific PCR and detected in 11/67 SCCHN patients (16.4%), with no significant differences 
according to site (oral cavity, pharynx, larynx).  Methylation of the miR-137 promoter was 
significantly associated with overall survival (Hazard Ratio = 3.68, 95% Confidence Interval: 
1.01-13.38) but not with disease-free survival or any of the prognostic factors evaluated.  This 
study indicates that miR-137 is methylated in tumor tissue from pharyngeal and laryngeal 
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squamous cancers, in addition to oral squamous cell carcinoma; and that miR-137 promoter 
methylation has potential utility as a prognostic marker for SCCHN. 
7.2 INTRODUCTION 
Head and neck cancer describes a heterogeneous group of malignancies occurring in the upper 
aerodigestive tract, the majority (93%) of which are squamous cell carcinomas (SCCHN) [3].  
The overall 5-year survival of approximately 60% among head and neck cancer patients has been 
virtually unchanged over the past 3 decades [20].  Despite therapeutic advances in cancer 
treatment, there has been no significant improvement in laryngeal cancer survival and only a 
slight gain in survival has been observed for cancers of the oral cavity and pharynx [3].  As 
treatments improve and become more targeted, there is a need to identify biomarkers that 
correlate with prognosis and/or prognostic factors in an attempt to understand mechanisms 
driving aggressive tumor behavior and to identify patients who are at greatest risk for mortality. 
MicroRNAs are small, non-coding RNA molecules that negatively regulate target gene 
expression through degradation and translational inhibition, with potentially hundreds of target 
mRNAs [201].  Alterations in the expression levels of microRNAs occur in most, if not all, types 
of cancer [9, 10, 17, 27, 200, 223-235], including SCCHN [9, 10, 27, 224, 234].  The potential 
prognostic value of microRNAs is suggested by their frequent involvement in proliferation, 
differentiation and apoptotic pathways.  Altered expression of individual microRNAs has been 
associated with survival [8-10, 12-16, 18, 19, 81, 238, 239, 293], tumor stage [11, 239], grade 
[19], lymph node metastasis [9, 14, 239] and vascular invasion [9, 11] in multiple tumor types. 
An estimated 10% of microRNAs are controlled by DNA methylation [7], with aberrant 
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methylation being one source of microRNA dysregulation.  Associations between microRNA 
promoter methylation and overall [238, 294, 295] and disease-free [294] cancer survival have 
been reported. 
MicroRNA-137 (miR-137) is located on chromosome 1p21.3 and lies across a large CpG 
island [17, 27].  Promoter methylation of miR-137 has been described in several solid tumors 
[27, 253, 272], including a report [27] that it is frequently methylated in tumor tissue from oral 
squamous cell carcinoma (OSCC).  A significantly higher frequency of miR-137 promoter 
methylation in oral rinse samples from SCCHN patients than from controls was recently reported 
by our group [296].  Cyclin-dependent kinase 6 (Cdk6) has been identified as a target of miR-
137, which interacts with Cyclin D1 to phosphorylate Rb allowing the cell to progress through 
the G1/S phase checkpoint [17, 27].  Experimental studies have shown that transfection of miR-
137 to deficient OSCC cell lines results in a reduction of Cdk6 levels and increased cell cycle 
arrest at the G1 phase [27].  Loss of control of the G1/S-phase checkpoint could reduce the 
capacity of the cell to repair DNA damage prior to synthesis, potentially resulting in genomic 
instability.   
Known prognostic factors for SCCHN include stage [3], tumor size and lymph node 
metastasis [36, 37], tumor grade [45] and surgical tumor margin positivity [46-48].  The primary 
objective of this study is to evaluate the prognostic value of miR-137 promoter methylation in 
SCCHN by assessing its association with overall and disease-free survival, as well as known 
prognostic factors for the disease. 
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7.3 MATERIALS AND METHODS 
            7.3.1 Study Population 
This study was conducted as a part of the University of Pittsburgh Head and Neck Cancer 
Specialized Program of Research Excellence (SPORE).  The study population consisted of 
consecutively diagnosed adult patients (> 18 years) at the University of Pittsburgh Medical 
Center (Pittsburgh, PA) between September 2007 and April 2009 with primary squamous cell 
carcinoma of the oral cavity, pharynx or larynx and no prior history of cancer.  Archival tumor 
tissue was available for 67/102 (65.7%) patients meeting these criteria.  Patients for whom 
cancer tissue was available did not significantly differ in terms of age, gender, cancer site or 
stage in comparison to patients without available tissue.  IRB approval was obtained under the 
University of Pittsburgh Head and Neck Cancer SPORE for sample collection and use of patient 
data.  All subjects provided written informed consent for participation in this study. 
            7.3.2 Data Sources 
Upon enrollment, patients completed an epidemiologic questionnaire providing detailed 
demographic and behavioral information.  Clinical data were extracted at the time of diagnosis 
and recorded in the University of Pittsburgh Head and Neck Oncology Registry.  Patients entered 
into the registry were prospectively followed for the ascertainment of vital status through 
February 8, 2010.  Formalin-fixed paraffin-embedded (FFPE) tumor tissue was obtained and 
evaluated by a board-certified pathologist to verify that representative sections were used. Tissue 
samples used in this study were collected prior to administration of radiation or chemotherapy. 
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            7.3.3 Methylation-Specific PCR 
DNA was extracted from tumor tissue with the DNeasy Blood and Tissue Kit (Qiagen, Valencia, 
CA).  Sodium bisulfite modification of the resultant DNA was performed using the EZ DNA 
Methylation Kit (Zymo Research, Orange, CA) per the manufacturer’s protocol.  Methylation 
status of miR-137 was determined by methylation-specific PCR (MSP), as previously described 
[296].  PCR products were analyzed by separation on high-resolution 4% agarose E-gels 
(Invitrogen, Carlsbad, CA) and visualized and digitally captured with an EDAS 290 high-
performance ultraviolet transilluminator using 1D 3.6 software (Kodak, Rochester, NY).  Each 
MSP reaction contained a fully methylated and unmethylated bisulfite converted human DNA 
(Qiagen, Valencia, CA) as a positive and negative control.  
            7.3.4 Statistical Analysis 
Descriptive statistics for the study population were generated by miR-137 methylation status for 
demographic, behavioral and clinical characteristics. Categorical variables were compared using 
Fisher’s exact tests.  The Skewness-Kurtosis test was used to evaluate normality of continuous 
variables [297].  In the case of non-normality, the Mann-Whitney U test was used for 
comparison; otherwise a two-sample t-test was used.   
Exact logistic regression [298] was used to model each prognostic factor of interest, 
conditioned on select covariates to adjust for potential confounding.  Prognostic factors for 
SCCHN included tumor stage at diagnosis, comparing advanced (stage III [T3 N0 M0 or T1-3 
N1 M0] or IV [T4 or > N2 or M1]) to local (AJCC stage group I [T1 N0 M0] or II [T2 N0 M0]); 
tumor size (T classification), comparing T3/T4 to T1/T2; lymph node positivity (N 
 73 
classification), comparing positive (N1 or greater) to negative (N0); tumor grade, comparing 
poorly differentiated to well/moderately differentiated; and surgical tumor margins, restricted to 
patients receiving surgical intervention, comparing patients with positive to patients with 
negative margins.  The primary exposure of interest was miR-137 promoter methylation 
(methylated/unmethylated).  Gender, smoking status (ever/never), daily fruit and vegetable 
consumption (above/below median) and tumor site were considered as covariates for each model 
based on the univariate results and predetermined biological importance.  Exact logistic 
regression results were compared to the results from asymptotic models using bootstrap variance 
estimators to assess comparability. 
Univariate Kaplan-Meier estimates were generated for 2-year overall and disease-free 
survival by miR-137 promoter methylation status.  Differences in survival by methylation status 
were assessed using log-rank tests.  In the analysis of disease-free survival, patients who died 
prior to recurrence were considered to be censored at death. 
Multivariable Cox proportional hazards models [299] provided estimates of overall and 
disease-free survival, adjusted for age, stage at diagnosis and tumor site. The proportional 
hazards assumption was tested for each model using an approach based on the slope of scaled 
Schoenfeld’s residuals as a function of time [300]. P-values ≤ 0.05 were considered to be 
statistically significant throughout. 
7.4 RESULTS 
SCCHN patients with miR-137 methylation-positive tumors ate fewer daily servings of fruits and 
vegetables (P = 0.005) and were more likely to be women (P = 0.13) relative to those with 
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unmethylated tumors (Table 10). Although not statistically significant, 10 of the 11 patients with 
miR-137 methylation  (90.9%) used both alcohol and cigarettes compared to 58.9% of 
unmethylated patients. 
 
Table 10.  Demographics of the study population and behavioral risk factors, by miR-137 methylation status 
 
 
Abbreviations: n = number, σ = standard deviation 
Note: all tests are two-sided 
a T-test 
b Fisher’s exact test 
c Mann-Whitney U test 
 
Promoter methylation of miR-137 was detected in tumor tissue from 16.4% (11/67) of 
SCCHN patients.  When considered by tumor site, miR-137 methylation was detected in 14.8% 
(4/27) of oral cancers, 22.7% (5/22) of pharyngeal cancers and 11.1% (2/18) of laryngeal cancers 
(Table 2).  The proportions of patients with miR-137 promoter methylation did not differ 
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significantly by tumor site (P = 0.71).  Univariate comparisons of SCCHN prognostic factors by 
miR-137 methylation status showed no other significant differences between patients with miR-
137 methylation-positive and methylation-negative tumors. 
 
Table 11.  Clinical Characteristics of the study population by miR-137 methylation status 
 
Abbreviations: n = number; AJCC = American Joint Committee on Cancer 
Note: all tests are two-sided 
a Fisher’s exact test 
b Excludes patients not treated with surgery  
 
Neither the crude nor adjusted exact logistic regression models showed any significant 
associations between miR-137 promoter methylation and stage at diagnosis, tumor size, nodal 
positivity, tumor grade or surgical tumor margin positivity for SCCHN, although confidence 
intervals are wide (Table 12).  Similar results were obtained from the asymptotic logistic 
regression models using a bootstrap variance estimator (not shown). 
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Table 12.  Crude and adjusted odds ratios (ORs) of SCCHN prognostic factors and miR-137 promoter 
methylation  
 
 
Abbreviations: OR = odds ratio; CI = confidence interval; AJCC: American Joint Committee on Cancer;  
n = number 
a Adjusted for smoking and fruit and vegetable consumption 
b Adjusted for gender, fruit and vegetable consumption and tumor site 
c Adjusted for gender and fruit and vegetable consumption 
d Adjusted for gender and tumor site 
e Model excludes patients not treated with surgery 
 
 
The average overall follow-up time was 15.2 months (median = 14.8; 10th percentile = 
7.8 months; 90th percentile = 22.9 months), with 14 deaths.  The average follow-up for disease-
free survival was 13.8 months (median = 13.1; 10th percentile = 4.3 months; 90th percentile = 
22.6 months), with 9 recurrences.   
 In univariate analyses, SCCHN patients with miR-137 promoter methylation had a 
significantly lower overall survival rate (P = 0.046) compared to those with unmethylated tumors 
(Figure 5).  No difference was observed for disease-free survival between patients with and 
without miR-137 promoter methylation (P = 0.63; Figure 6). 
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Figure 5. Kaplan-Meier estimate of overall survival for SCCHN patients by miR-137 methylation status 
 
 
Figure 6. Kaplan-Meier estimate of disease-free survival for SCCHN patients by miR-137 methylation status 
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In the multivariable Cox proportional hazards analysis adjusting for age, stage at 
diagnosis and tumor site (Table 13), SCCHN patients with tumors positive for miR-137 promoter 
methylation had a significantly poorer overall survival (HR = 3.68, 95% CI: 1.01-13.38) 
compared to those with unmethylated tumors.  Promoter methylation of miR-137 was not 
associated significantly with disease-free survival. 
 
Table 13.  Crude and adjusted hazard ratios (HRs) for overall and disease-free survival in SCCHN patients 
by miR-137 methylation status 
 
 
Abbreviations: HR = hazard ratio; CI = confidence interval; n = number 
a Adjusted for age, stage at diagnosis and tumor site 
7.5 DISCUSSION 
Dysregulation of microRNA expression has been correlated with outcome or prognostic factors 
for many different cancer types [8-16, 18, 19, 238, 239, 293].  Aberrant promoter methylation is 
one mechanism through which microRNA expression can be suppressed. There have been recent 
reports in the literature of associations of promoter methylation of individual microRNAs and 
cancer prognosis [238, 294, 295], including correlation of miR-124a, another microRNA that 
targets Cdk6, with poorer overall and disease-free survival in acute lymphocytic leukemia 
patients [294].   Here, we report the detection of miR-137 promoter methylation in tumor tissue 
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of 16.4% of SCCHN patients, occurring in oral, pharyngeal and laryngeal cancers; and describe 
an association of miR-137 promoter methylation with poorer overall survival among SCCHN 
patients.  To our knowledge, this is the first study to evaluate the potential prognostic value of 
promoter methylation of a microRNA in SCCHN.   
The observed association between miR-137 promoter methylation and overall survival 
among SCCHN patients may relate, in part, to the involvement of miR-137 in cell-cycle control 
through regulation of Cdk6.  Loss of miR-137 expression results in reduced ability of the cell to 
arrest at the G1 phase, increasing proliferation [17, 27], which may lead to accumulation of DNA 
damage thus enhancing genomic instability.  Another potential contributor is the possible role of 
miR-137 in cellular differentiation.  Expression levels of miR-137 are reported to be elevated in 
neuronal differentiation and decreased in poorly differentiated gliomas [17], although it is 
presently unknown if this generalizes to other histologies.  Contrary to this point, we found no 
association of miR-137 promoter methylation with tumor grade, although low statistical power 
limits our ability to detect such an association.  In spite of its purported involvement in cell cycle 
control, we also found no significant associations of miR-137 promoter methylation with other 
SCCHN prognostic factors, including stage, tumor size, nodal involvement or surgical tumor 
margin positivity.   
Strengths of this study include high-quality prospective data collection; employment of 
methylation-specific PCR, a relatively inexpensive and sensitive method to detect DNA 
methylation for ascertainment of miR-137 methylation status; and the use of surgical tumor 
tissue taken prior to initiation of radiation and/or chemotherapy, which precludes potential bias 
relating to treatment effects.  Another strength is our use of exact logistic regression modeling to 
obtain more accurate inferences for small sample sizes [298]. 
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This study also has several limitations.  The relatively small sample size and proportion 
of miR-137 methylation-positive samples limits our power to detect associations with prognostic 
factors.  The present study has power ranging from 10%-18% to detect an association with an 
OR of 2.0.  Another limitation is the relatively short follow-up time; future studies with longer 
follow-up time are needed to confirm our observed association between miR-137 promoter 
methylation and overall survival and further assess the association with disease-free survival. 
Another aspect that needs to be addressed in future studies is the correlation of promoter 
methylation with miR-137 expression. Only one previous study with a small sample size has 
suggested a negative correlation between the two [27].  Despite methylation-specific PCR being 
a tried-and-true sensitive method for detection of promoter methylation [301], it is not 
quantitative.  MicroRNA-137 methylation-positive tumors, as detected by methylation-specific 
PCR, may contain a low percentage of methylated alleles, which may not be sufficient to 
produce a substantial reduction of miR-137 expression, and this could dilute the magnitude of an 
association between methylation and prognosis/outcome.  
 The results of this study suggest that miR-137 promoter methylation is a relatively 
common occurrence in SCCHN, occurs across all sites, and may have value as a prognostic 
biomarker for the disease.  However, future research efforts should focus on quantitative 
methylation analysis; further evaluation of the prognostic value of miR-137 promoter 
methylation in expanded cohorts with longer follow-up; and assessment of the combined effect 
of loss of multiple tumor suppressors involved in regulation of the G1/S phase checkpoint.  
Continued efforts to identify such novel prognostic biomarkers or biomarker panels are crucial in 
reaching the greater goal of understanding the biology behind aggressive tumor behavior, and 
ultimately improving survival and reducing mortality from head and neck cancer. 
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    8.0  PREDICTIVE VALUE OF ORAL RINSES FOR THE DETECTION OF MIR-137 
    PROMOTER METHYLATION IN TUMOR TISSUE FROM SQUAMOUS CELL 
CARCINOMA OF THE HEAD AND NECK 
8.1 ABSTRACT 
Head and neck cancer accounted for an estimated 48,010 incident cancers and 11,260 deaths in 
the US in 2009, the majority of which are squamous cell carcinoma, and inflicts substantial 
morbidity, including disfigurement and loss or hindrance of basic upper aerodigestive tract 
functions.  Novel diagnostic and prognostic biomarkers and sample collection techniques that 
facilitate marker ascertainment are needed in order to reduce the mortality and morbidity burden.  
Oral rinse is a non-invasive DNA collection method that has shown promise in detection of 
promoter methylation biomarkers for SCCHN.  Presently, there are few studies that formally 
evaluate the ability of oral rinse to predict methylation status in tumor tissue and none regarding 
promoter methylation of microRNA.  Therefore the goal of this study is to assess the predictive 
value of oral rinse in prediction of miR-137 methylation status in SCCHN tumor tissue.  We have 
obtained paired oral rinse and tumor tissue samples from 64 patients with incident SCCHN.  
Methylation status of miR-137 was determined by methylation-specific PCR for both oral rinse 
and tumor samples; and sensitivity, specificity, and positive and negative predictive values were 
calculated.  Our results indicate that oral rinse is only a fair predictor of miR-137 methylation 
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status in tumor tissue (sensitivity = 45.5%; specificity = 81.1%).  Continued efforts at 
determining the best technique for sample collection via oral rinse and optimal biomarkers to be 
used in conjunction with it are required in order to establish oral rinse as a valid method for 
SCCHN screening. 
8.2 INTRODUCTION 
Head and neck cancer describes a heterogeneous group of malignancies arising in the upper 
aerodigestive tract, estimated to have resulted in 48,010 cases and 11,260 deaths in the United 
States in 2009 [1] and more than 500,000 annual cases and 300,000 deaths globally [2].  
Squamous cell carcinoma of the head and neck (SCCHN) makes up the majority (93%) of these 
cancers [3].  Although head and neck cancer only accounts for 2.0% of US and 4.5% of global 
cancer-deaths, it bears substantial morbidity, including disfigurement and impairment of basic 
functions, such as talking, swallowing, eating and breathing.  Thus, identification of novel 
biomarkers and practical methods of sample collection that can be used in a clinical setting is 
desired to reduce the impact of the disease. 
Oral rinse is a non-invasive technique for DNA collection from the upper aerodigestive 
tract. In addition to cells exfoliated directly into the rinse, epithelial cells from the mouth and 
throat, including tumor cells, may be shed into saliva and picked up by the collection media.  
Several studies have evaluated the use of oral rinse or saliva as a tool for detection of DNA 
promoter methylation in subjects with premalignant or malignant head and neck tumors [21, 23-
26, 199], although half of these studies have limited their evaluation to lesions of the oral cavity 
[24, 25, 199], likely due to their direct contact with the collection media.  Only 4 of the studies 
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offer a direct comparison of saliva or oral rinse to tumor tissue [23-26], although to date, no 
study has formally evaluated the predictive value of oral rinse or saliva for detection of promoter 
methylation for SCCHN in a site-specific manner (e.g. oral cavity, pharynx, larynx).  
Furthermore, published reports have been limited to a relatively small subset of tumor suppressor 
genes, and oral rinse has never before been assessed for promoter methylation of a microRNA. 
 We recently reported the presence of miR-137 promoter methylation in 21.2% of oral 
rinse samples from SCCHN patients [296]. The highest prevalence of miR-137 methylation 
occurred in oral rinse samples taken from patients with oral tumors, and the lowest from tumors 
of the larynx.  One could speculate that oral rinse is simply better at detecting oral lesions as a 
result of anatomy: oral tumors come in direct contact with the collection media and thus are more 
apt to be exfoliated during the rinsing process, as opposed to laryngeal tumors, which are less 
likely to come in contact with the rinse. However, as history has often demonstrated, the 
seemingly obvious logical answer is not always the correct one.  Therefore, the primary goal of 
this study is to formally estimate the predictive value of oral rinse for the detection of miR-137 
promoter methylation in SCCHN tumor tissue, overall and by site. 
8.3 MATERIALS AND METHODS 
            8.3.1 Study Population 
This study was conducted as a part of an epidemiology project within the University of 
Pittsburgh Head and Neck Specialized Program of Research Excellence (SPORE).  The study 
population consisted of 64 patients with primary SCCHN and available paired tumor tissue and 
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oral rinse samples, diagnosed at the University of Pittsburgh Medical Center (Pittsburgh, PA) 
from September 2007 to April 2009, with no prior history of non-cutaneous cancer.  Primary 
tumors of the nasopharynx were excluded. IRB approval was obtained under the University of 
Pittsburgh Head and Neck Cancer SPORE for sample collection and use of patient data.  All 
patients provided written informed consent for participation in this study. 
 
            8.3.2 Data Sources and Sample Collection 
Patient demographic and behavioral risk factor information was obtained from an epidemiologic 
questionnaire completed by patients upon study enrollment.  Clinical data was obtained from the 
University of Pittsburgh Head and Neck Oncology Registry.  Oral rinse samples were collected 
prior to treatment by having patients swish for 20-30 seconds with 20 ml of sterile saline.  
Following the rinse, 10 ml of commercial mouthwash (Scope) was added to the samples as a 
DNA preservative, after which the sample was frozen at -20°C until DNA extraction.  Tumor 
DNA was obtained from archival formalin-fixed paraffin-embedded (FFPE) tissue, collected 
prior to initiation of radiation or chemotherapy.  SCCHN tissue samples were reviewed by a 
board-certified pathologist to ensure that representative sections were captured. 
 
            8.3.3 Methylation-Specific PCR   
DNA was extracted from oral rinse samples using the Puregene DNA Purification Kit (Gentra 
Systems, Minneapolis, MN) and from tumor tissue with the DNeasy Blood and Tissue Kit 
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(Qiagen, Valencia, CA).  Following extraction, DNA concentrations were quantified using the 
NanoDrop 1000 spectrophotometer (ThermoFisher Scientific, Waltham, MA).  Sodium 
bisulfite modification of the DNA was performed with the EZ DNA Methylation Kit (Zymo 
Research, Orange, CA) per the manufacturer’s protocol, inputting 1 µg of untreated DNA and 
eluting 10 µl of bisulfite converted DNA per sample.  Methylation status of miR-137 was 
determined by methylation-specific PCR, as previously described [296], using 2 µl of template 
bisulfite converted DNA per reaction per sample.  PCR products were analyzed by 
electrophoresis on high-resolution 4% agarose E-gels (Invitrogen, Carlsbad, CA) and visualized 
and digitally captured with an EDAS 290 high-performance ultraviolet transilluminator using 1D 
3.6 software (Kodak, Rochester, NY).  Fully methylated and unmethylated bisulfite converted 
human DNA (Qiagen, Valencia, CA) was included in each PCR batch as positive and negative 
controls.  Any samples producing faint positive bands were rerun twice, and only those that were 
consistently positive were considered methylated. 
 
            8.3.4 Statistical Analysis 
Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) 
were estimated for SCCHN, overall and by site, considering miR-137 methylation in oral rinse to 
be the diagnostic test and tumor tissue to be the gold standard.  Exact binomial 95% confidence 
intervals [302] were calculated for each of the aforementioned statistics.  Youden’s Index [303] 
was calculated as a measure of overall accuracy of oral rinse in predicting miR-137 methylation 
status in tumor tissue. 
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 Among patients with miR-137 methylation-negative tumor tissue, key attributes of those 
with miR-137 methylation-positive oral rinse were compared to those with methylation-negative 
oral rinse to determine if this occurrence (miR-137 methylation-positive oral rinse with negative 
tumor) was a random event.  The Skewness-Kurtosis test was used to assess normality of 
continuous covariates [304]. Fisher’s exact test was used for comparison of categorical 
covariates; and the Mann-Whitney U test or 2-sample t-test was used for continuous covariates 
with non-normal or normal distributions, respectively. 
 
8.4 RESULTS 
A contingency table (Table 14) is provided to illustrate concordance and discordance for 
detection of miR-137 promoter methylation between paired oral rinse and SCCHN tumor tissue 
(N = 64).  There were 48 (75.0%) patients with concordant results between oral rinse and tumor 
tissue: 5 methylated and 43 unmethylated.  There were a total of 10 patients for whom miR-137 
was methylated in DNA obtained from oral rinse but not in the SCCHN tumor tissue; and 6 
patients for whom oral rinse failed to detect miR-137 promoter methylation in positive tumor 
tissue.   
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Table 14.  Comparison of miR-137 promoter methylation detected in oral rinse and SCCHN tumor tissue, 
overall and site-specific 
 
 
 
Measures of predictive value for oral rinse in detecting miR-137 promoter methylation in 
SCCHN tumor tissue are presented in Table 15.  The sensitivity of oral rinse for predicting miR-
137 promoter methylation status in SCCHN was 45.5% (95% CI: 16.8% - 76.6%), specificity 
was 81.1% (95% CI: 68.0% - 90.6%), PPV was 33.3% (95% CI: 11.8% - 61.6%) and NPV was 
87.8% (95% CI: 75.2% - 95.4%).  Youden’s Index, as a measure of overall accuracy, was 0.266. 
 
Table 15.  Measures of predictive value of oral rinse for detection of miR-137 promoter methylation in 
SCCHN tumor tissue 
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When restricted to patients with tumors arising in the oral cavity (Table 15), the 
sensitivity for oral rinse was 75.0% (95% CI: 19.4% - 99.4%), specificity was 66.7% (95% CI: 
43.0% - 85.4%), PPV was 30.0% (95% CI: 6.7% - 65.3%) and NPV was 93.3% (95% CI: 68.1% 
- 99.8%).  Youden’s Index for oral rinse in subjects with oral cavity tumors was 0.417.  For 
patients with pharyngeal tumors (Table 15), the sensitivity was 20.0% (95% CI: 0.5% - 71.6%), 
specificity was 88.2% (95% CI: 63.6% - 98.5%), PPV was 33.3% (95% CI: 0.8% - 90.6%) and 
NPV was 79.0% (95% CI: 54.4% - 94.0%).  Youden’s Index for oral rinse in patients with 
pharyngeal tumors was 0.082.  For patients with laryngeal tumors (Table 15), the sensitivity was 
50.0% (95% CI: 1.3% - 98.7%), specificity was 93.3% (95% CI: 68.1% - 99.8%), PPV was 
50.0% (95% CI: 1.3% - 98.7%) and NPV was 93.3% (95% CI: 68.1% - 99.8%).  Youden’s Index 
for oral rinse in patients with laryngeal tumors was 0.433.   
A comparison of key attributes between patients with miR-137 methylation-positive oral 
rinse but negative tumor tissue and those with negative oral rinse and tumor tissue is presented in 
Table 16.  By contrast, those with methylation positive oral rinse samples and negative tumor 
were on average 8.5 years older (P = 0.009), smoked for 12 more years (P = 0.012) and had 
lower median body mass index (BMI) by 4.5 kg/m2 (P = 0.023).  There was also a borderline 
difference in duration of alcohol consumption, where patients with miR-137 methylation-positive 
oral rinse and negative tumor drank for an average of 9.6 years longer (P = 0.062).  
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Table 16.  Comparison of patients with miR-137 promoter methylation in oral rinse but not tumor to those 
with negative oral rinse and tumor  
 
 
a Positive for miR-137 methylation in oral rinse and negative in tumor tissue   
b Negative for miR-137 methylation negative in oral rinse and tumor tissue  
c 2-sample t-test 
d Fisher's exact test 
e Mann-Whitney U test 
f  Restricted to ever smokers 
g Resticted to ever drinkers 
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8.5 DISCUSSION 
Tumor DNA may be readily shed in to saliva or oral rinse samples, which can be easily collected 
in a non-invasive fashion in a clinical setting.  At present, few studies have evaluated oral rinse 
or saliva as a mode of DNA collection for detection of promoter methylation [21, 23-26, 199, 
296]; and less has been done in comparing results obtained from oral rinse or saliva to those 
obtained from tumor tissue, with 4 studies taking up this task [23-26] and only 2 reporting 
measures of validity or reliability [23, 25].  Moreover, only 2 of the studies include pharyngeal 
and laryngeal tumors in the comparison [23, 26], one of which presents a validity or reliability 
measure [23], although not in a site-specific manner. All of these publications have evaluated 
protein-coding genes, with most looking at limited sets of genes.  Here we report for the first 
time an overall and site-specific comparison of oral rinse and tumor DNA for detection of 
promoter methylation of a microRNA in SCCHN patients. 
Our findings indicate that oral rinse is only a fair predictor of miR-137 promoter 
methylation in tumor tissue, with an overall sensitivity and specificity of 45.5% and 81.1%, 
respectively.  When evaluated by tumor site, the sensitivity was higher in OSCC but at the cost 
of specificity, while oral rinse had a low sensitivity for pharyngeal and laryngeal tumors but had 
good specificity.  Righini and colleagues calculated kappa coefficients for detection of 
methylation for each of 11 genes in SCCHN patients [23] with values ranging from 0.47-0.86, 
indicating fair to very good concordance.  By comparison, our kappa coefficient (calculated post-
hoc) for detection of miR-137 promoter methylation in SCCHN was 0.23.  Viet and colleagues 
present percent positive agreement for 5 genes detected in saliva from OSCC patients, with 
values ranging from 12.5% - 87.5% [25].  Post-hoc estimation of our percent positive agreement 
produces a value of 38.5%, which lies within the range of their results.   
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Some of the discrepancies between studies may be explained by differences in genes 
analyzed.  Even within studies, there is variation in correlation by gene.  Moreover, only 11 total 
genes were evaluated between the two studies, all of which were protein-coding genes, whereas 
we have evaluated methylation of a microRNA. There is an underlying assumption that 
regulation of microRNAs via promoter methylation is similar to that of protein-coding genes; 
however, it is entirely conceivable that this is not the case, as our understanding of epigenetic 
control of microRNA is still in the nascent stages. 
Methodological differences between studies may also account for some of the between-
study disparities.  We collected oral rinse samples by having our subjects swish with 20 ml of 
sterile saline for 20-30 seconds; whereas Righini and colleagues, who also employed 
methylation-specific PCR (MSP) and whose study found the best correlation between oral rinse 
and tumor tissue, had their study subjects swish and gargle for 3 minutes, increasing total 
exposure of tumor DNA to the rinse and bringing it in contact with the pharyngeal epithelium.  
In contrast, Viet and colleagues collected whole saliva for analysis using a methylation-specific 
quantitative RT-PCR (MethyLight) assay.  Additionally, our study and the Viet study extracted 
DNA from formalin-fixed paraffin-embedded (FFPE) tissue to ascertain tumor methylation 
status, as opposed to fresh-frozen tumor tissue by Righini and colleagues, who found better 
agreement between oral rinse and tumor.  Compared to fresh-frozen tissue, DNA derived from 
FFPE tumor tissue is of a lower quality as a result of cross-linking and fragmentation [305].  
Thus it is likely that MSP has a lower sensitivity in FFPE tumor tissue relative to fresh-frozen 
tissue.     
We observed 10 instances in which the oral rinse sample was positive for miR-137 
methylation but the tumor tissue was negative.  Of the 4 studies comparing oral rinse or saliva to 
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tumor tissue, 3 report no occurrences of methylation-positive oral rinse or saliva with negative 
tumor [23, 24, 26]; the fourth study, by Viet and colleagues [25], which is the only one of the 4 
studies that used FFPE tumor tissue, also had no such occurrences, per personal communication 
with the authors.  However, a small study that evaluated oral rinse for detection of 
nasopharyngeal cancer (N = 30) reported one such instance [22].  One possible explanation for 
this is the development of field defects, arising as a result of chronic exposure of the upper-
aerodigestive tract epithelium to carcinogens, such as alcohol and tobacco, resulting in 
accumulation of molecular insults and giving rise to distinct subclones, which may or may not 
develop into cancer. With this in mind, it is conceivable that miR-137 promoter methylation 
sometimes occur in non-cancerous epithelium away from the tumor, resulting in its detection in 
oral rinse but not tumor tissue.  Adding support to this notion is our post-hoc analysis comparing 
patients with miR-137 promoter methylation detected in oral rinse but not tumor tissue to those 
with both negative oral rinse and tumor tissue.  This revealed that this phenomena does not affect 
subjects at random but rather these patients were on average 8.5 years older, smoked for 12 years 
longer and had a lower median BMI by 4.5 kg/m2.  It is recognized that as we age, the frequency 
of aberrant promoter methylation increases [132]. Differential patterns of DNA methylation 
occur even among monozygotic twins.  These differences increase with age and are most 
apparent between twins spending longer portions of their lifetimes apart, suggesting an 
environmental interaction [135].   Although there is likely a positive correlation between age and 
smoking duration, longer exposure time to cigarette smoke may also contribute to miR-137 
promoter methylation in non-cancerous epithelium.  Future studies with adequate follow-up time 
are needed to determine if patients with miR-137 methylation-positive oral rinse samples and 
negative tumor tissue are at greater risk of developing tumor recurrences. 
 93 
Alternatively, the detection of miR-137 promoter methylation in oral rinse but not tumor 
may be due to reduced sensitivity of MSP in tumor tissue as a result of using low-quality DNA 
derived from FFPE tumor tissue, as previously discussed.  However, this is rather unlikely given 
the heterogeneity of DNA collected by oral rinse and that Viet and colleagues, who also used 
FFPE tumor tissue, did not observe this.  Furthermore, we input a fairly high amount of template 
DNA (~160 ng) per sample per PCR reaction, assuming an 80% DNA recovery rate following 
bisulfite conversion.  False-positive MSP results for oral rinse does not appear to be the issue, as 
we previously compared oral rinses from 99 SCCNHN patients and 99 cancer-free control 
subjects [296], blinded to case-control status during MSP, and observed miR-137 promoter 
methylation in only 3% of controls compared to 21.2% of cases.  
 Although it has promise as a non-invasive collection media, there appears to be 
substantial inter- and intra-study variability in the ability of oral rinse to predict methylation 
status in tumor tissue, depending upon methodology and the gene of interest.  Oral malignancies 
are the most appealing cancers in which to study oral rinses and saliva collection due to direct 
contact with the fluid.  However, oral cancer by itself may be too rare a disease to warrant 
population screening and is more amenable to detection via visual examination as compared to 
pharyngeal and laryngeal cancers.  Rather, methods should be sensitive and specific for detection 
of methylation markers in all SCCHN.  Future studies should aim at further determination of the 
most reliable and valid method for oral rinse collection, while minimizing invasion, and at 
identification of sensitive and specific biomarker panels in oral rinse that can be used in a clinical 
setting to aid in the early diagnosis of SCCHN in an effort to reduce morbidity and mortality 
from this disease. 
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9.0  CONCLUSIONS 
Head and neck cancer describes a heterogeneous class of malignancies that occur in the upper 
aerodigestive tract, the majority of which are squamous cell carcinoma (SCCHN).  It is the 9th 
most common cancer in the United States, accounting for an estimated 48,010 new cases and 
11,260 deaths in 2009 [1].  The 5-year survival for the disease is approximately 60% [20], and 
despite therapeutic advances there has been little improvement over the past 3 decades. In 
addition to mortality, SCCHN bears substantial morbidity, including disfigurement and 
dysfunction, such as difficulty talking, swallowing, eating or breathing. As would be expected, 
prognosis worsens with increasing stage at diagnosis, which is problematic since approximately 
two-thirds of patients are diagnosed at an advanced stage (stage III or IV) [20].  Thus, there is a 
need for identification of biomarkers that can aid in the early detection or prognostication of 
SCCHN. 
Insensitivity to anti-growth signals due to loss of tumor suppressor gene function or 
expression is considered to be one of the hallmarks of cancer [306].  Epigenetic dysregulation, 
including promoter methylation, is at least as common as mutation in causing tumor suppressor 
gene inactivation.  Promoter methylation of tumor suppressor genes can occur in the early stages 
of carcinogenesis [4, 125, 160], including the development of SCCHN [25], making them 
potentially useful markers for early detection of disease.  Additionally, promoter methylation is 
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detected in DNA samples, which is a relatively stable source that can be readily obtained from 
patients. 
MicroRNAs are involved in negative regulation of their target genes and are capable of 
controlling up to hundreds of targets.  Dysregulation of their expression occurs in many different 
cancer types [9, 10, 17, 27, 200, 223-235], including SCCHN [9, 10, 27, 224, 234]. It is 
estimated that 10% of microRNAs are regulated via promoter methylation [7], which generally 
results in transcriptional silencing. Therefore, aberrant promoter methylation of a microRNA can 
potentially affect numerous cellular functions, thus making their methylation intriguing for 
biomarker research.  
The goal of this dissertation project was to evaluate miR-137 promoter methylation as an 
etiologic and prognostic biomarker for SCCHN.  Specifically, it sought to determine if miR-137 
promoter methylation could be detected in tumor tissue and oral rinses taken from SCCHN 
patients and assess its association with SCCHN; to identify potential risk factors for miR-137 
promoter methylation in oral rinses from SCCHN patients; to assess the prognostic value of miR-
137 promoter methylation in tumor tissue; and to estimate the predictive value for oral rinse in 
detection of miR-137 promoter methylation in SCCHN tumor tissue using methylation-specific 
PCR.  
As a result of this effort, miR-137 promoter methylation was identified in DNA from 
tumor tissue and oral rinses of SCCHN patients, making this the first report of its occurrence in 
pharyngeal and laryngeal cancers; and found a strong association between its detection in oral 
rinse samples and SCCHN, marking the first time that promoter methylation of a microRNA was 
assessed using oral rinse or saliva samples. Some risk factors for miR-137 promoter methylation 
in SCCHN patients were also elucidated, which had never been previously attempted, with 
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identification of a strong positive association with female gender and an inverse association with 
body mass index (BMI). This study was also the first assessment of the prognostic value of miR-
137 promoter methylation in SCCHN, finding poorer overall survival among SCCHN patients 
with miR-137 methylation-positive tumors.  Finally, this was the initial study to evaluate the 
predictive value of oral rinse for detection of microRNA promoter methylation in tumor tissue. 
However, there was only fair concordance between oral rinse and tumor tissue for miR-137 
promoter methylation from SCCHN patients, overall and by site; and there were several 
instances where oral rinse DNA was positive for methylation but SCCHN tumor tissue was 
negative. This was contrary to reports by other similar studies, although those studies were 
limited to a small subset of protein-coding tumor suppressor genes. This finding may signify that 
miR-137 promoter methylation is acting as a marker for extensive field damage of the upper 
aerodigestive tract epithelium, possibly due to chronic carcinogen exposure, rather than a true 
marker of disease. 
Overall, this investigation suggests that although miR-137 promoter methylation detected 
in oral rinse samples has a low sensitivity for detection of SCCHN, it has potential as a 
diagnostic biomarker in DNA methylation panels, particularly because of its high specificity. It 
also indicates that miR-137 promoter methylation in tumor tissue may have utility as a prognostic 
marker for SCCHN. Future directions for research include quantitative analysis of miR-137 
promoter methylation; confirmation and additional evaluation of risk factors in studies with 
larger sample sizes; further assessment of the association of miR-137 promoter methylation with 
overall and disease-free survival in expanded cohorts with longer follow-up; optimization of oral 
rinse sample collection techniques; and evaluation of miR-137 promoter methylation interaction 
with other biomarkers, particularly those involved in cell cycle control at the G1/S-phase 
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checkpoint. Continued efforts at discovery of novel biomarkers for SCCHN, such as miR-137 
promoter methylation, will make positive contributions to overall public health by leading to 
earlier detection and better prognostic classification, thus reducing the morbidity and mortality 
burden that ensues from this disease. 
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APPENDIX A: BACKGROUND SUPPLEMENT   
A.1 HEAD AND NECK CANCER SUPPLEMENT 
A.1.1 Expanded Global Epidemiology of Head and Neck Cancer 
Regional incidence of head and neck cancer differs by site and varies drastically (Figure 7).  
Highest-risk areas for oral cavity and pharyngeal cancer include France, Switzerland, Italy, 
Spain, India, the United States (African-Americans), Australia, New Zealand and Melanesia.  
There is more than 20-fold difference in incidence between the highest-risk regions and the 
lowest-risk regions, which include China, Scandinavian countries and the United Kingdom [2, 
71, 307].  Areas that are high-risk for laryngeal cancers include southern and central Europe, the 
United States (African-Americans), southern Brazil, Uruguay and Argentina; while Southeast 
Asia and central Africa have the lowest risk [2, 71, 307].  Mortality rates also exhibit site- and 
region-specific variability (Figure 8). The highest mortality from oral cavity and pharyngeal 
cancer occurs in India, Southeast Asia, southern Africa, West Africa (oral cavity), Europe 
(excluding Scandinavia), Russia, and Melanesia.  Regions with the highest mortality from 
laryngeal cancer include Russia, Spain, Argentina, and Namibia [307]. 
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Figure 7. Global incidence of head and neck cancer by region, site and gender; age-adjusted to the WHO 
World standard population  
 
Source: IARC, Globocan (2002) [307] 
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Figure 8.   Global mortality of head and neck cancer by region, site and gender; age-adjusted to the WHO 
World standard population  
 
Source: IARC, Globocan (2002) [307] 
 
Global gender differences are slightly more pronounced than what is observed in the US.  
Overall, men are 2.96 times more likely than women to be diagnosed with head and neck cancer, 
excluding nasopharyngeal cancers, and 3.07 times more likely to die from it.  It ranks 6th in both 
incidence and mortality among men and 10th in incidence and 11th in mortality among women 
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[2].  When considering site-specific cancers, there is still a male predominance but the magnitude 
of the disparity varies by site.  Men are 1.79 times as likely as women to be diagnosed with 
cancer of the oral cavity, 4.41 times as likely to be diagnosed with pharyngeal cancer and 6.96 
times as likely to be diagnosed with laryngeal cancer.  The male-to-female ratio of mortality by 
site mirrors the incidence and is 1.73, 4.24 and 6.94 for oral cavity, pharynx and larynx 
respectively [307].  In men, incidence rates are highest for cancers of the oral cavity, followed 
closely by larynx, and are lowest in pharynx [307] (Table 17).  However, mortality rates are 
similar among all 3 sites.  For women, the incidence and mortality rates are by far the highest for 
oral cavity, with relatively low rates in the pharynx and larynx (Table 17).  
 
Table 17.  World incidence and mortality rates and 1-year prevalence by gender  
   Male     Female   
Site IR* MR* 
1-Year 
Prevalence IR* MR* 
1-Year 
Prevalence 
Oral Cavity 6.3 2.9 133,993 3.2 1.5 75,769 
Pharynx 3.8 2.5 71,982 0.8 0.5 16,630 
Larynx 5.1 2.9 108,722 0.6 0.4 15,463 
Total 15.2 8.3 314,697 4.6 2.4 107,862 
       
* per 100,000, age-standardized to WHO World standard  population   
 
Source: IARC, Globocan (2002) [307] 
A.1.2 Survival Disparities by Health Insurance Status 
There are also prognostic disparities associated with health insurance status of patients with 
SCCHN.  Compared to patients with private insurance, those who are uninsured or have 
Medicaid coverage are more likely to present with advanced stage disease and lymph node 
involvement [308, 309] and have 50% poorer survival [309]. 
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A.1.3 Economic Costs 
The overall cost of SCCHN to society is substantial.  In the United States, SCCHN accounts for 
$2.02 billion in direct, morbidity and mortality costs annually (2001 US dollars) [310].  
Additionally, it is estimated that SCCHN is responsible for $2.8 billion per year in lost 
productivity [311].  Oral and pharyngeal squamous cancer results in 133,900 person-years of life 
lost per year [35].  The median 1-year cost of treatment from 1995-2000 was $22,658 and 
$27,655 for patients with early- and late-stage disease, respectively [312].  Medicare SCCHN 
patients spend an average of 8.7 hospital-days and 13.7 physician visits per year in contrast to 
Medicare patients without cancer, who average 1.8 hospital-days and 10.9 physician visits [312]. 
A.1.4 US Smoking Trends 
As of 2005, 20.9% of Americans (45 million) were current smokers, down from a high of 42.5% 
in 1965, with an additional 21.6% (47 million) who were former smokers.  This has been 
accompanied by a sharp reduction in annual per capita cigarette consumption since 1965.  
Conversely, the number of never-smokers has increased substantially since 1965, climbing to 
57.5% of the population (124 million) in 2005, up from a low of 44.0% [313, 314].  However, 
due to population gains, the absolute number of current smokers has remained relatively stable 
over the past 4 decades.  There is a 10-15 year lag in SCCHN incidence as it relates to reductions 
in smoking among the population.  As such, age-adjusted incidence (2000 US standard) of 
SCCHN has decreased in the US since the 1980s, reflecting reductions in per capita cigarette 
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consumption that began in the 1970s [31, 315].  Mortality rates have also declined over the past 
2 decades [31], mostly due to decreasing incidence since there have been minimal gains in 
survival during this time [3].  These declines are across all races and gender, although there are 
still major disparities, particularly for men and African-Americans. 
 
A.1.5 US Alcohol Consumption Trends 
There was a decreasing trend in alcohol consumption in the US from the 1900s to 1940, followed 
by an increasing trend until 1980, after which consumption steadily declined [316]. In 2002, 
51.0% of Americans (120 million) were current drinkers (at least 1 drink in the past 30 days), 
22.9% (54 million) were binge drinkers (5 or more drinks on 1 occasion in the past 30 days) and 
6.7% (15.9 million) were heavy drinkers (5 or more drinks on the same occasion 5 or more times 
in the past 30 days) [317].  Males were more likely to be current drinkers compared with 
females.  Adult excessive drinkers, defined as those averaging 2 or more alcoholic drinks per 
day, account for 46.3% of total US alcohol consumption, and the heaviest drinkers (top 2.5%) 
consume 27% of the total [318].   
A.1.6 Additional Risk Factors for SCCHN 
Diet 
Dietary factors have also been implicated in SCCHN.  Diets high in animal fat and low in fruit 
and vegetable consumption have been associated with SCCHN [89, 319-323].  Vitamin A and 
beta-carotenes may have a protective effect, while vitamin A deficiency has been associated with 
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SCCHN [33, 72].  Some studies have reported an association with folate deficiency and SCCHN, 
although the literature has been inconsistent [324-326]. 
 
Environmental and Occupational Exposures 
Occupational exposures are more commonly associated with nasopharyngeal carcinomas but 
play a minor role in development of squamous cancers of the oral cavity, pharynx or larynx 
[327].  However, there have been a few reports correlating metalworking with laryngeal 
carcinoma [328, 329]. Exposure to toxins during mustard gas production has also been 
associated with increased risk of pharyngeal and laryngeal cancers with approximately 3- and 5-
fold increases in risk, respectively [330].  There have been mixed results regarding associations 
of SCCHN with exposure to asbestos [331, 332] and exposure to wood dust [328, 333], although 
IARC classifies wood dust as a group 1 carcinogen with a clear association with nasopharyngeal 
carcinoma [334].   
Indoor air pollution may also contribute to the development of SCCHN.  Heating and 
cooking with fossil fuels, including oil, coal, gas and woodstoves, has been associated with 
SCCHN, with increased risk ranging from 1.6- to 3.6-fold [335-337].   
The US Environmental Protection Agency (EPA) classifies environmental tobacco smoke 
as a human carcinogen [338].  Measurable levels of tobacco metabolites have been found in the 
urine and blood of non-smokers exposed to second-hand smoke [339, 340].  Chronic exposure to 
environmental tobacco smoke has been associated with a 1.5- to 5-fold risk for SCCHN, with a 
dose-response relationship [341-343]. 
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Gastroesophageal Reflux 
Several observational studies have found an association between gastroesophageal reflux 
and laryngeal and pharyngeal cancer [344-346].  This is substantiated by multiple studies 
reporting a high prevalence of gastric reflux into the laryngopharnyx, based on 24-hour 
pH probe monitoring [347-349]. 
 
Human Immunodeficiency Syndrome 
An excess of SCCHN has been reported among HIV-positive individuals [350]. Risk of 
oropharyngeal high-risk HPV infection was found to be 9.2% higher among HIV-positive 
adults compared to HIV-negative adults [351].  Moreover, HIV-infected men were found 
to have 3-fold higher risk of tonsilar carcinoma, which is commonly associated with 
HPV-16 infection, compared with the general population [352]. Although much of the 
excess risk is likely attributable to immunosuppression and HPV infection, it should be 
noted that HIV-positive populations as a whole are more likely to engage in other risk 
factors for SCCHN, particularly smoking and drinking, relative to the general population. 
A.1.1 Common Genetic Alterations 
Head and neck squamous cell carcinoma is characterized by complex karyotypes with a 
non-random pattern of recurrent losses and gains of chromosomal regions [353].  
Common genetic alterations in SCCHN involve activation of oncogenes or inactivation 
of tumor suppressor genes, resulting in tumor progression.  A schematic of common 
events in SCCHN development is shown in Figure 9. 
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Figure 9.  Model of common genetic alterations in the development of SCCHN  
Adapted from: Perez-Ordonez B (2006) [354] 
 
Loss of heterozygosity (LOH) is the loss of expression of both normal copies of a gene, 
which can lead to the inactivation of tumor suppressor genes.  Loss of heterozygosity of 
chromosome region 9p21 is among the most common events in SCCHN development, occurring 
early in the progression of head and neck squamous tumors.  It is found in 70-80% of dysplastic 
and malignant lesions and is commonly a result of hypermethylation or deletion [353-355].  
Embedded in this region is the CDKN2A locus, which encodes tumor suppressors p16INK4A and 
p14ARF [353-355].  The p16INK4A protein is involved with regulation of the G1 phase in the cell 
cycle through inhibition of the CDK4/6-cyclinD1 complex, preventing it from phosphorylating 
the retinoblastoma (Rb) protein, resulting in arrest of cell-cycle progression [353-355]. 
Expression of p16 is lost in 83% of oral squamous cell carcinomas and 60% of premalignant 
conditions [356-358].  The p14ARF protein interacts with the MDM2 protein to stabilize p53 and 
prevent its degradation [353-355].   
Loss of heterozygosity also frequently occurs at chromosomal region 3p early in SCCHN 
tumorigenesis and is found in 60-70% of SCCHN [353-355].  The specific 3p locus is presently 
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uncharacterized, but 4 distinct regions whose loss is associated with SCCHN have been 
identified: 3p14, 3p21, 3p24, and 3p26 [354].  As with 9p21, loss of these regions is commonly a 
result of hypermethylation or deletion.  Among the genes contained in these loci are tumor 
suppressors FHIT (3p14) and RASSF1A (3p21), each of which has been found to be inactivated 
in a small subset of SCCHN [353, 354].  Thirty percent of benign hyperplasias, an early 
premalignant change, contain LOH at 3p, 9p21, or both [359, 360]. 
Another site commonly associated with LOH is chromosomal region 17p, which tends to 
occur at a later stage of tumorigenesis compared with 9p21 and 3p, and is involved in the 
progression of dysplasia to invasive SCCHN [353-355].  Loss of heterozygosity of 17p occurs in 
50-70% of SCCHN, commonly as a result of mutation or deletion [354].  The p53 gene is 
included in this region (17p13) [353].  Mutation of p53 has been associated with exposure to 
tobacco and alcohol, and results in loss of genomic stability leading to increased rates of 
mutations [355]. 
Amplification of chromosomal region 11q13 occurs in 30-60% of SCCHN [353-355].  
This region contains the oncogene CCND1, which encodes cyclin-D1. Amplification results in 
upregulation of cyclin-D1, a protein involved in the progression of the cell cycle from G1 to S-
phase by forming a complex with CDK4/6 and phosphorylating pRb, releasing transcription 
factor E2F [353-355].  In addition to conferring a growth advantage, overexpression of cyclin-
D1 is associated with lymph node metastasis and poor prognosis [354].   
One of the best-studied oncogenes associated with SCCHN is the Epidermal Growth 
Factor Receptor (EGFR).  Expression of EGFR is upregulated in 80-90% of SCCHN [112, 353].  
EGFR is known to activate pathways related to proliferation, apoptosis, invasion, angiogenesis 
and metastasis [112].  Overexpression of EGFR or its ligand, Transforming Growth Factor 
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Alpha (TGF-α), occurs early in tumorigenesis and increases progressively during the transition 
from dysplasia to SCCHN [361, 362].  Elevated expression has been shown to be predictive of 
worse overall and disease-free survival [363]. 
Telomerase has been shown to be reactivated in 90% of SCCHN and premalignant 
lesions [364].  It is involved in telomere maintenance and is not normally expressed in somatic 
cells, thus preventing unlimited replication.  Activation of telomerase results in cellular 
immortality, one of the hallmarks of cancer [306]. 
A.1.8 HPV-Mediated Oncogenesis 
As previously discussed, HPV-mediated SCCHN is a distinct pathological entity.  High-risk 
HPV-mediated carcinogenesis operates primarily through the expression of the E6 and E7 viral 
oncoproteins.  These proteins bind to and facilitate ubiquitin-mediated degradation of p53 and 
pRb tumor suppressors, respectively [109].  By inactivating p53, E6 disrupts the G1/S 
checkpoint and results in the loss of p53-mediated apoptosis.  The inactivation of pRb by E7 
releases the E2F transcription factor, allowing transcription of S-phase related genes for cell 
cycle progression.  Additionally, expression of HPV16 E6 and E7 oncoproteins results in cellular 
immortalization [109] and have been shown to predispose the cell to genomic instability [109].  
Furthermore, the E7 oncoprotein of HPV-16 stimulates the activity of DNMT1, potentially 
leading to aberrant promoter hypermethylation [185].  Compared with HPV-negative SCCHN, 
HPV-positive tumors are more likely to have wild-type p53, more likely to overexpress p16 and 
less likely to have amplification at chromosomal region 11q13 [365]. 
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A.2 EPIGENETIC SUPPLEMENT 
A.2.1 Histone Modifications 
Promoter methylation is not the sole epigenetic mechanism capable of silencing gene expression.  
Modification of histone proteins can result in the alteration of chromatin structure, directly 
affecting gene transcription, DNA repair, DNA replication and chromosomal organization [4, 
120].  Histones are protein octamers, containing 2 of each of H2A, H2B, H3, and H4, around 
which approximately 146 bp of DNA is wound, forming a nucleosome [120].  The nucleosome is 
a recurring structure of eukaryotic DNA that comprises the chromosomes, condensing the DNA 
so that the entire genome can fit into the nucleus.  Most chromatin exists as tightly compacted 
nucleosomes, called heterochromatin, which is transcriptionally incompetent.  This is 
represented by the dark staining portion of the nucleus on light microscopy.  Euchromatin has 
less compact nucleosomes, forming an open chromatin structure that can be readily transcribed.  
This appears as the lightly staining portion of the nucleus on light microscopy [120]. 
Histone modification occurs in different histone proteins, histone variants and histone 
residues such as lysine, arginine and serine.  Modifications typically involve addition or removal 
of acetyl or methyl groups to the histone proteins at the N-terminal tails protruding from the 
nucleosomes [4, 120]. 
Histone acetylation is associated with transcriptional activation. In transcriptionally 
active promoters with unmethylated cytosines, histones are acetylated by histone acetyl 
transferases (HAT).  These form a complex with transcription activator and coactivator proteins 
to initiate transcription. Conversely, histone deacetylases (HDAC) form complexes with methyl-
CpG-binding-proteins (MBD) and methylated cytosines in the promoter, allowing them to 
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remove acetyl groups from the N-terminal tails of the histones, causing condensation of the 
nucleosome, resulting in transcriptional inactivation [4, 120]. 
Histone methylation can result in either transcriptional activation or repression, 
depending upon the protein and amino acid type methylated and its position in the histone tail [4, 
120].  It can also have different degrees, including mono-, di- and trimethylation.  Histone 
methylation is catalyzed by a class of enzymes called histone methyltransferases, while histone 
demethylases are responsible for demethylation [120, 366].  Trimethylation of lysine at position 
9, 27, or 36 of the N-terminal tail of H3 (H3-K9, H3-K27, or H3-K36) or lysine at position 20 on 
H4 (H4-K20) results in chromosomal structure alterations (heterochromatin) leading to 
transcriptional silencing.  Trimethylation of lysine at position 4, 36, or 79 on H3 (H3-K4 or H3-
K79) is associated with a euchromatin conformation and active transcription [366-368].  Several 
other covalent methyl histone modifications have been identified, but their precise effects on 
transcription are presently unknown [120]. 
A.2.2 CpG Methylation and Point Mutations 
DNA point mutations, if left unrepaired, can cause alterations or loss of function of genes, 
potentially resulting in dysregulation of cellular function.  There are 3 general mechanisms 
through which CpG methylation can induce point mutations: deamination of 5-meC, 
enhancement of exongenous carcinogens and silencing of DNA repair genes. 
The first mechanism is endogenous.  Methylated cytosine can undergo hydrolytic 
deamination causing a C to T transition [120]. The frequency of C to T methylation-associated 
transitions varies by tissue-type, probably due to tissue-specific differences in mismatch repair 
[120].  More than 30% of disease-related germline point mutations occur at CpG dinucleotides 
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[120]. Nearly half of all somatic and one-third of all germline p53 mutations take place at 
methylated CpGs, and many common p53 mutations that manifest in somatic cells are caused by 
C to T transitions, including “hot spot” mutations at codons 248, 273, and 282 [369]. The risk of 
p53 mutation at 5-meC is 10-fold that of unmethylated cytosine, and CpG dinucleotides in these 
regions have been observed to be methylated in normal tissue [369]. 
Secondly, DNA methylation can enhance the mutagenic effect of exogenous carcinogens 
[120].  An example of this is the affinity of benzo(α)pyrene diol epoxide (BPDE) for adduct 
formation on guanines adjacent to 5-meC, resulting in G to T transversions in aerodigestive tract 
cancers in smokers [151, 152, 370].  Similarly, acrolein has an affinity for binding 5-meC, 
leading to C to T transitions [153].  Also, the addition of a methyl group changes the light 
absorption wavelength for cytosine, favoring formation of pyrimidine dimers in skin DNA upon 
UV exposure [120]. 
Finally, promoter methylation can induce gene silencing of DNA repair genes.  This 
results in increased risk of unrepaired mutation accumulation, which can ultimately lead to 
malignancy [120]. 
A.3 MICRORNA SUPPLEMENT 
A.3.1 Post-transcriptional microRNA Processing 
There are several steps involved in the post-transcriptional processing of miRNA.  The primary 
transcript, called pri-miRNA, is typically 3 to 4 kilobases in length with a 5’ 7-methylguanosine 
(m7G) cap and poly-adenylated (poly-A) tail, similar to mRNA [244].  Following transcription, a 
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stable hairpin structure of at least 30 bp is necessary to serve as the initiation signal for the 
processing steps [371].  The pri-miRNAs are cleaved in the nucleus by a multiprotein complex 
called Microprocessor, composed of the RNase III enzyme Drosha and double-stranded RNA-
binding domain (dsRBD) protein DGCR8/Pasha, producing one or more precursor miRNAs 
(pre-miRNA) [6, 200-203].  DGCR8/Pasha recognizes the junction of single and double-stranded 
RNA at the base of the pri-miRNA hairpin, binding Microprocessor to it, allowing Drosha to 
cleave it [371].  Pri-miRNAs often contain several pre-miRNAs, known as clusters.  
Microprocessor activity can be inhibited through direct competitive binding of RNA-binding 
nuclear proteins [371-373], structural alterations of pri-miRNA [372] or direct protein interaction 
with Microprocessor [371]. 
Pre-miRNAs are 65-100 nucleotides long with a hairpin structure containing a double-
stranded RNA stem [371].  Exportin 5 (Exp5) recognizes the 3’ overhang, which is characteristic 
of pre-miRNA, and a portion of the RNA duplex structure [375, 376] and transports the pre-
miRNA from the nucleus to the cytoplasm.  Once in the cytoplasm, the pre-miRNA is bound by 
a protein complex called RISC-loading complex (RLC), which consists of another RNase III, 
called Dicer, along with Argonaut 2 and TRBP proteins [6, 200-203, 370].  Dicer recognizes the 
stem of the hairpin structure as double-stranded RNA and cleaves it on the loop side, leaving an 
18-25 base pair miRNA duplex (miRNA:miRNA*) [6, 200-203, 208].   
The strand of the duplex with its 5’ end on the less thermodynamically stable end of the 
duplex, termed the guide strand, is retained and becomes the mature miRNA [377, 378]. The 
other strand, denoted as miRNA*, is removed and degraded [6, 200-203].  This is facilitated by 
Dicer, which also may help stabilize the miRNA and play a role in mRNA target identification 
[208].  The mature miRNA is then incorporated into a protein complex formed with an Argonaut 
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family (Ago) protein, called RNA Induced Silencing Complex (RISC) [6, 200-203, 208].  There 
are 4 Argonaut proteins expressed in humans, of which only Ago 2 possesses endonucleolytic 
activity [208].   
A.3.2 Mirtrons 
Mirtrons are a class of miRNAs that originate from short intronic hairpins and bypass the 
Microprocessor cleavage step [379, 380].  Alternatively, they are expressed in conjunction with 
their host gene and are processed via the splicing mechanism and lariat-branching enzyme and 
rejoin miRNA processing at the nuclear export step.  
A.3.3 Positive Regulation of Gene Expression by MicroRNA 
In addition to negative regulation, there is recent evidence that some miRNAs may also function 
as positive regulators of gene expression.  MicroRNAs, miR-369-3 and let-7, have been reported 
to induce transcription of Tumor Necrosis Factor-α (TNF-α) by interacting with its AU (adenine 
and uracil)-rich elements (ARE) in the 3’ UTR during cell-cycle arrest [381].  In contrast, during 
cellular proliferation, let-7 negatively regulates TNF-α expression [381]. 
A.3.4 MicroRNA Regulation of Epigenetics 
Alternatively, miRNAs can regulate epigenetics by targeting transcripts of genes involved in 
epigenetic regulation [6].  The miR-29 family and miR-148 have been reported to target 
DNMT3a and/or 3b, leading to reduced expression, global hypomethylation and decreased 
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methylation of hypermethylated promoter CpG islands [382, 383].   The miR-290 cluster has 
been shown to target Rbl-2, a repressor of DNMT3a and 3b.  Therefore loss of miR-290 
expression results in increased expression of DNMT3a and 3b [384, 385].  Additionally, 
miRNAs have been reported to target enzymes involved in histone modification [386-388]. 
A.3.5 Non-Epigenetic Mechanisms of MicroRNA Dysregulation 
Transcriptional Dysregulation 
Dysregulation at the transcriptional level is one way that miRNA expression can be altered.  For 
example, transcription of miR-210 is dependent on Hypoxia Inducible Factor [373], miR-34 is a 
direct target of the p53 transcription factor [229], and miR-17-92 transcription is induced by c-
Myc [390, 391].  In contrast, Nuclear Factor I/A (NFI-A) binds to the promoter of miR-223 
during human granulocyte differentiation, inhibiting transcription [374].  Changes in levels of 
such transcriptional promoters/repressors can lead to variation in miRNA expression. 
 
Dysregulation of Processing Pathways 
Another mechanism through which miRNA expression can be modified is via functional changes 
in the processing pathways.  Dysregulation of the Drosha or Dicer processing steps results in 
down-regulation of miRNAs [375].  This is one of the major causes of decreased global miRNA 
expression in cancer [375].  Furthermore, reduced Dicer expression correlates with decreased 
survival among lung cancer patients [376]. Additionally, single-nucleotide polymorphisms 
(SNP) have been identified in pri-, pre- and mature miRNAs in various cancers that have been 
shown to alter miRNA expression by increasing [395] or decreasing levels of miRNA [396-398].  
For example, a SNP in pre-miR-196a2 was associated with an increase in mature miRNA levels 
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but not pre-miRNA levels, suggesting that the alteration affects Dicer processing of the pre-
miRNA to its mature form [395]. 
 
Target mRNA Modifications 
Modifications of target mRNA altering the miRNA binding-site, such as mutations or 
translocations, can affect miRNA function [377].  Functional SNPs in miRNA-binding 
sequences in the 3’ UTR of target mRNAs that result in altered protein expression have been 
described in several cancers [222, 400-402] and have been associated with survival [400] and 
drug resistance [378].   
 
Reversal of Translational Silencing 
RNA-binding proteins can reverse miRNA-mediated translational repression by binding the 3’ 
UTR of mRNA.  For instance, HuR binds the 3’ UTR of CAT-1 under conditions of stress, 
signaling the release of miR-122/RISC, allowing CAT-1 to leave the P-body and become 
translationally active [379].   Aberrant expression of such proteins could result in changes in 
levels of miRNA targets. 
 
Copy Number Alterations and Mutations 
Copy number alterations may also influence miRNA expression.  Amplification can increase 
miRNA levels, while deletions can reduce or eliminate expression.  Furthermore, mutations or 
translocations of miRNA can alter its functionality, such as its ability to bind to its target mRNA.  
Approximately 50% of known miRNAs are located in or near fragile sites and in regions prone 
to loss of heterozygosity, amplifications and common breakpoints associated with cancer [380].  
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A.3.6 Oncogenic microRNAs and SCCHN 
Oncogenic miRNAs that are differentially expressed in SCCHN include miR-21 and miR-184. 
Mir-21 has been reported to be upregulated in oral, pharyngeal and laryngeal squamous cell 
carcinomas [224], which is supported by the findings of Tran and colleagues that it is highly 
expressed in SCCHN [254].  Moreover, it is also upregulated in other cancers, including breast, 
lung, thyroid, liver, ovary, pancreas and glioblastoma [223]. Known targets of mir-21 include 
PDCD4 [405] and PTEN [406] tumor suppressors, both of which are involved in apoptotic 
signaling. Furthermore, loss of heterozygosity of PTEN is a common event [407, 408] and 
PDCD4 is underexpressed [10] in SCCHN. MicroRNA-184 has been reported to be upregulated 
in squamous cell carcinoma of the tongue [234].   When lingual squamous cancer cell lines were 
transfected with miR-184 inhibitor, there was a decrease in cellular proliferation, reduced 
expression of the c-Myc oncogene, and increased apoptosis [234]. 
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APPENDIX B:  LABORATORY PROTOCOLS 
B.1 DNA EXTRACTION 
B.1.1 DNA Extraction from Oral Rinse Samples 
DNA was extracted from oral rinse samples using the Puregene DNA Purification Kit (Gentra 
Systems, Minneapolis, MN) for DNA extraction from buccal cells in mouthwash.  All samples 
were pelleted by centrifugation for 10 minutes at 3400 rpm.  Pellets were then frozen at -20° C 
until the start of the DNA extraction process. 
Cells were lysed via the addition of 1000 µl of cell lysis solution and 5 µl of RNase A 
solution (4 mg/ml) to the cell pellet directly into the 50 ml conical tube, which was subsequently 
incubated for 15 minutes at room temperature.  After incubation, to complete cell lysis, 10 µl of 
proteinase K solution (20 mg/ml) was added to the lysate, vortexed vigorously for 20 seconds 
and incubated for 10 minutes at room temperature.  The sample was then divided into two 1.5 ml 
microfuge tubes (500 µl each). 
 To precipitate any protein in the lysate, 170 µl of protein precipitate solution was added 
to each microfuge tube, the samples were vortexed for 20 seconds and placed in an ice bath for 
10 minutes. They were then centrifuged for 10 minutes to pellet the protein precipitate.  The 
supernatant from each tube was transferred into a clean 1.5 ml microfuge tube containing 500 µl 
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of isopropanol and 2.5 µl of glycogen solution (20 mg/ml) and centrifuged for 5 minutes to 
precipitate the DNA.  The supernatant was discarded and the remaining protein pellet washed by 
adding 500 µl of EtOH and centrifuging for 1 minute.   The EtOH was discarded and the DNA 
pellet allowed to air dry. 
DNA was hydrated in 200 µl of DNA hydration solution overnight and then stored at -
20°C until ready for use.  DNA concentration was determined using the Thermo Scientific 
NanoDrop 1000 Spectrophotometer (ThermoFisher Scientific, Waltham, MA). 
B.1.2 DNA Extraction from Formalin-Fixed Paraffin-Embedded SCCHN Tissue 
DNA was extracted from formalin-fixed paraffin-embedded SCCHN tissue using the DNeasy 
Kit (Qiagen, Valencia, CA), following a modified version of the manufacturer’s protocol, 
detailed below. 
Three 10-micron thick curls from formalin-fixed paraffin-embedded tissue blocks from 
each subject with available tumor tissue were obtained from the University of Pittsburgh Head 
and Neck Tissue Bank, provided in 1.5 ml microfuge tubes.  A board-certified pathologist 
reviewed slides cut from the beginning and end of each section of the cut tissue to ensure that 
tissue samples were representative of the tumor. 
The first overarching step in the extraction process was to deparaffinize the tissue.  Each 
sample was incubated for 30 minutes at 60°C in a heat block to melt the paraffin.  If necessary, 
tissue was carefully pushed down into the bottom of the tube using sterile, autoclaved toothpicks.  
Following incubation, 1 ml of 100% xylene was added to each tube and centrifuged for 5 
minutes, after which the supernatant was carefully poured off, and this step was repeated two 
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more times.  Next, three EtOH washes were subsequently performed using 500 µl of EtOH 
solutions each, where the first used 100% EtOH centrifuged for 3 minutes; the second 75% 
EtOH centrifuged for 3 minutes; and the final used 50% EtOH centrifuged for 5 minutes.  After 
each spin, the supernatant was carefully poured off into a sterile 1.5 ml microfuge tube, so that 
the pellet would not be lost if it broke loose with the supernatant.  Following the final wash, the 
tissue was allowed to dry under the hood before proceeding with the protocol. 
The next overarching step in the DNA extraction process involved the tissue lysis.  After 
drying the tissue under the hood, 300 µl of Buffer ATL (provided in the DNeasy kit) was added 
to each tube, followed by the addition of 100 µl of proteinase K (also provided).  The samples 
were thoroughly mixed by vortexing and incubated overnight at 56°C in a shaking incubator set 
at 150 rpm, in which samples were suspended at a 45° angle.   
The final overarching step of the DNA extraction process is the actual DNA extraction 
from the lysed tissue.  Following overnight incubation, each sample was vortexed for 15 
seconds. Next, 400 µl of Buffer AL (provided in the DNeasy kit) was added, the samples were 
vortexed again, and incubated at 70°C for 10 minutes.  After incubation, 400 µl of 100% EtOH 
was added to each sample and then vortexed.  Half of the solution was pipetted into DNeasy spin 
columns, labeled with the respective sample identifier, placed in a 2 ml collection tube, and 
centrifuged at 8000 rpm for 1 minute.  The flow-through was discarded and the process was 
repeated using the second half of each sample using the same spin column.  Each spin column 
was then placed in a new collection tube and 500 µl of Buffer AW1 (provided in the DNeasy kit) 
was added.  The tubes were centrifuged at 8000 rpm for 1 minute and the collection tube and 
flow-through were discarded.  The spin columns were placed in new collection tubes and 500 µl 
of Buffer AW2 (provided in the DNeasy kit) was added.  The sample was centrifuged at 14,000 
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rpm for 3 minutes, after which the collection tube and flow-through were discarded. The spin 
column was then placed in a 1.5 ml microfuge tube, 50 µl of Buffer AE (provided in the DNeasy 
kit) was added and incubated at room temperature for 1 minute, and then centrifuged at 8,000 
rpm for 1 minute to elute the DNA.  This step was then repeated, for a final volume of 100 µl of 
eluted DNA solution.  The DNA concentration of each sample was then quantified using the 
NanoDrop 1000 Spectrophotometer (ThermoFisher Scientific, Waltham, MA). Samples were 
stored at -20°C until bisulfite conversion and methylation-specific PCR. 
B.2 BISULFITE CONVERSION AND RECOVERY 
Sodium bisulfite conversion is a technique used in methylation analysis to discriminate between 
methylated and unmethylated cytosines.  After bisulfite treatment, methylated cytosines are 
preserved as cytosines, while unmethylated cytosines are deaminated and converted to uracil and 
subsequently amplified as thymine in the PCR reaction [381].  Following treatment, the forward 
and reverse strands are no longer complementary as a result of conversion of unmethylated 
cytosines to thymines, which can no longer pair with the guanine on the opposite strand (Figure 
15) [381].  PCR reactions can be designed to amplify either the top (plus) or bottom (minus) 
strand. 
The bisulfite conversion and recovery step was performed using the EZ DNA 
Methylation Kit (Zymo Research, Orange, CA). 
Prior to starting the protocol, the CT Conversion reagent included in the kit was prepared 
by adding 750 µl of sterile water and 210 µl of M-Dilution buffer to one tube of CT Conversion 
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reagent and mixed by vortexing every 1-2 minutes for a total of 10 minutes.   CT Conversion 
reagent is photosensitive, so light exposure should be avoided, and therefore was used 
immediately following preparation.  Additionally, the M-Wash buffer was prepared by adding 24 
ml of 100% EtOH to the M-Wash buffer concentrate. 
The first step of the bisulfite conversion process was the addition of 5 µl of the M-
Dilution buffer to 500 ng of sample DNA, adjusting the volume to 50 µl using sterile water.  In 
cases where the DNA concentration was less than 11.1 ng/µl (< 500 ng in 45 µl) a total of 45 µl 
of DNA was used.  
Next, the samples were incubated at 37° C for 15 minutes.  Following incubation, 100 µl 
of CT Conversion reagent was added to each sample and incubated in the dark at 50° C for 12-16 
hours.  The samples were then placed on ice for 10 minutes. Next, 400 µl of M-Binding buffer 
was added to each sample and loaded into a Zymo Spin I column, which was placed into a 2 ml 
collection tube and centrifuged at 10,000 g for 30 seconds.  The subsequent flowthrough was 
discarded following each centrifugation step. Two hundred µl of M-Wash buffer was added to 
the column and again centrifuged at 10,000 g for 30 seconds. Two hundred µl of M-
Desulfination buffer was added to the column, allowed to incubate at room temperature for 15 
minutes, and centrifuged at 10,000 g for 30 seconds. Two hundred µl of M-Wash buffer was 
added and centrifuged for 30 seconds, followed by the addition of another 200 µl of M-Wash 
buffer, centrifuged for 2 minutes.  Finally, 10 µl of M-Elution buffer was added directly to the 
matrix of each spin column, which was placed into a 1.5 ml microfuge tube and centrifuged for 1 
minute to elute the DNA.  The bisulfite converted DNA was diluted 1:10 and either used 
immediately or stored at -80° C.   
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B.3 METHYLATION-SPECIFIC PCR  
Methylation-specific PCR (MSP) is a bisulfite-dependent polymerase chain reaction-based assay 
that allows for the detection of DNA promoter methylation of a target gene [301]. Due to its use 
of PCR amplification, the assay has a high sensitivity capable of detecting methylation in as little 
as 0.1% of alleles in the sample [411]. 
 The assay requires 2 sets of primers: 1 specific for methylated DNA and 1 specific for 
unmethylated DNA. The primer sets are designed to amplify the same DNA sequence.  
Following PCR amplification, results are obtained via gel electrophoresis.  Detection of bands 
for either the methylated sequence or both methylated and unmethylated sequences signifies the 
presence of promoter methylation.  
The sequences for the methylation- and unmethylated-specific primers for the miR-137 
promoter region were designed using Methyl Primer Express software v 1.0 (Applied 
Biosystems, Foster City, CA).  Primer sites were checked for genetic polymorphisms using the 
Ensemble Genome Browser [382] and were determined to be free of common variants.  Each 
primer set for miR-137 (methylated and unmethylated) has an expected amplicon of 86 bp. The 
MSP primer sequences are provided in Table 18.  
 
Table 18.  Primer sequences for the miR-137 methylation-specific PCR (MSP) assay 
Specificity Sequence 
Annealing 
Temp 
Length 
(bases) CpGs 
Methylation  58ºC   
  Forward primer 5' GCGGTAGTAGTAGCGGTAGC 3'  20 3 
  Reverse primer 5' ACCCGTCACCGAAAAAAA 3'  18 2 
No methylation  51ºC   
  Forward primer 5' GGTGGTAGTAGTAGTGGTAGT 3'  21 --- 
  Reverse primer 5' TACCCATCACCAAAAAAAA  19 --- 
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 The MSP assay for miR-137 promoter methylation was performed following bisulfite-
conversion of the sample DNA (previously described in section 2.3.2).  Separate master mixes 
are required for the primer sets specific for methylated and unmethylated DNA.  The master mix 
for the assay included 5 µl of 10X PCR buffer II; 5 µl of 25 mM MgCl2; 5 µl of 10X nucleotide 
mix; 2 µl each of forward and reverse primer (10 pmol/µl); 0.5 µl of TaqGold DNA polymerase; 
and 28.5 µl of sterile water, for a master mix volume of 48 µl. 
 Initially, 2 µl of bisulfite converted fully methylated and unmethylated DNA was added 
to 24 wells each for the methylated and unmethylated reactions, respectively (for a total of 48 
wells.  A temperature gradient was performed to determine the optimal annealing temperature for 
the primer sets using a 96-well thermocycler, with annealing temperatures ranging from 47º C to 
62º C.  Ten µl of amplified product was added to 1 µl of 6x Loading Buffer and 9 µl of sterile 
water and run on high-resolution 4% agarose E-gels (Invitrogen, Carlsbad, CA) for 30 minutes.  
The optimal annealing temperature was selected by identifying the temperature with the best 
resolution for methylated and unmethylated DNA. 
For MSP, 48 µl of each respective master mix was added to each well along with 2 µl of 
sample DNA (for a total reaction volume of 50 µl) for the PCR reaction, which was performed 
under the cycling conditions provided in Table 19.  Each sample occupies 2 wells (1 for the 
methylated DNA reaction and 1 for the unmethylated reaction).  Each PCR reaction contained 
both positive and negative controls using fully-methylated and unmethylated bisulfite converted 
DNA (Qiagen, Valencia, CA) and negative controls using 2 µl sterile water in place of template 
DNA. 
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Table 19.  Cycling conditions for MSP 
  
Methylation-
Specific   
Unmethylation-
Specific 
Step Temperature Time Step Temperature Time 
1 94° C 2 min 1 95° C 5 min 
2 95° C 30 s 2 95° C 30 s 
3 64° C 30 s 3 51° C 30 s 
4 72° C 30 s 4 72° C 30 s 
Cycle step 4 to step 2, 4 times Cycle step 4 to step 2, 35 times 
5 95° C 30 s 5 72° C 4 min 
6 61° C 30 s 6 4° C pause 
7 72° C 30 s    
Cycle step 7 to step 5, 4 times    
8 95° C 30 s    
9 58° C 30 s    
10 72° C 30 s    
Cycle step 10 to step 8, 26 times    
11 72° C 5 min    
12 4° C pause    
 
 
Following PCR amplification, 1 µl of Loading Buffer and 9 µl of sterile water were 
added to 10 µl of each sample (for a total of 20 µl).  Analysis was performed on high-resolution 
4% agarose E-gels (Invitrogen, Carlsbad, CA) using a 100 bp marker (5 µl of Hyperladder V) 
with 5 samples per gel.  Samples were loaded in series, pairing methylated and unmethylated 
reactions for each subject.  Amplicons were visualized via an EDAS 290 high-performance 
ultraviolet transilluminator using 1D 3.6 software (Kodak, Rochester, NY).  Presence of a band 
was indicative of a positive signal.  Samples were considered methylated if there was a positive 
signal for either the methylation-specific reaction alone or both methylation- and unmethylation-
specific reactions.   
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  APPENDIX C: STATISTICAL ANALYSIS SUPPLEMENT       
C.1 CHAPTER 6 ANALYTIC SUPPLEMENT 
C.1.1 Preliminary Data Checks for Logistic Regression Model Building 
Logistic regression model selection for MicroRNA-137 Promoter Methylation in Oral Rinses 
from Patients with SCCHN was based on Hosmer and Lemeshow’s strategy for model selection 
[383]. 
 
Association of miR-137 Promoter Methylation with Case-Control Status 
Univariate differences in potential personal and behavioral risk factors were assessed between 
SCCHN patients and cancer-free control subjects, as described in the Materials and Methods 
(section 6.3.4).  Sparse or empty cells were collapsed for categorical variables.  Kernel density 
plots were generated for continuous covariates by case-control status to ensure overlap and 
preliminarily assess functional form (Figure 10).   
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Figure 10.  Kernel density plots of continuous covariates by case-control status 
 
Continuous covariates were plotted against the logit function to assess univariate linearity, where 
case-control status was the outcome of interest (Figure 11). 
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Figure 11.  Logit transformed lowess smoother plots of continuous covariates with case-control as the 
dependent variable 
 
Covariates with non-linear relationships with the logit were either transformed to achieve 
linearity or treated categorically. 
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Evaluation of Potential Risk Factors for miR-137 Promoter Methylation 
Univariate differences in potential personal and behavioral risk factors were assessed by miR-137 
promoter methylation status, as described in the Materials and Methods (section 6.3.4).  Sparse 
or empty cells were collapsed for categorical variables.  Kernel density plots were generated for 
continuous covariates by miR-137 promoter methylation status to ensure overlap and 
preliminarily assess functional form (Figure 12). 
 
 
Figure 12.  Kernel density plots of continuous covariates by miR-137 methylation status 
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 Continuous covariates were plotted against the logit function to assess univariate 
linearity, where miR-137 methylation status was the outcome of interest (Figure 13). 
 
 
Figure 13.  Logit transformed lowess smoother plots with miR-137 methylation status as the dependent 
variable of interest 
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Covariates with non-linear relationships with the logit were either transformed to achieve 
linearity or treated categorically. 
C.1.2 Assessment of Poorly-Fit and Influential Points in Logistic Regression Models 
Cook’s Distance [384] and deviance residuals [385] were calculated and plotted against each 
other to assess influential and poorly fit points, respectively, for each logistic regression model 
(Figures 14-17).  Sensitivity analysis was subsequently conducted excluding the most influential 
points based on the plots. 
 
 
 
Figure 14.  Cook’s Distance versus deviance residual plot for the case-control model for the association of 
miR-137 promoter methylation and SCCHN 
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Figure 15.  Cook's Distance versus residual deviance plots for the main case-series model for the association 
of miR-137 promoter methylation and potential risk factors 
 
 
 
Figure 16.  Cook's Distance vs residual deviance plot for case-series model including daily fruit and vegetable 
consumption 
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Figure 17.  Cook's Distance vs deviance residual plot for case-series model including stage at diagnosis 
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C.2 CHAPTER 7 ANALYTIC SUPPLEMENT 
C.2.1 Preliminary Data Checks for Cox Proportional Hazards Model Building 
Categorical covariates considered for use in the multivariable Cox proportional hazards models 
were tabulated by miR-137 methylation status and sparse or empty cells were collapsed.  A two-
way kernel density plot was generated for age (the only continuous covariate considered for the 
models) by miR-137 promoter methylation status to ensure overlap (Figure 18). 
 
 
Figure 18.  Kernel density of age by miR-137 methylation status for the multivariable Cox proportional 
hazards models 
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C.3 POWER CALCULATIONS 
C.3.1 Association of miR-137 Promoter Methylation and SCCHN 
Statistical power for the association of miR-137 promoter methylation and SCCHN was 
calculated overall and by site using the logistic regression function of PASS (NCSS, Kaysville, 
UT) for detection of odds ratios of 1.5, 2.0, 2.5 and 3.0 (Table 20), where alpha = 0.05.  The 
estimates were based on a total sample size of 198 for the overall calculation; and 136, 136 and 
124 for oral cavity, pharyngeal and laryngeal, respectively. For SCCHN, the baseline event 
probability (P0; based on model intercept coefficient) was estimated at 0.65 and the frequency of 
X = 1 was 24%; for tumors of the oral cavity, P0 = 0.25 and the frequency of X= 1 was 13%; for 
pharyngeal tumors, P0 = 0.49 and the frequency of X=1 was 6%; and for laryngeal tumors, P0 = 
0.23 and the frequency of X=1 was 4%. 
 
Table 20.  Power calculations for the association of miR-137 promoter methylation and SCCHN, overall and 
site-specific 
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C.3.2 Assessment of Risk Factors for miR-137 Promoter Methylation 
Statistical power for the association of miR-137 promoter methylation and potential risk factors 
in oral rinse from SCCHN patients was calculated using the logistic regression function of PASS 
(NCSS, Kaysville, UT) for detection of odds ratios of 1.5, 2.0, 2.5 and 3.0 (Table 21), where 
alpha = 0.05.  The baseline probability (P0) was based on the model intercept coefficient or the 
probability at the mean for binary and continuous covariates, respectively.  Power estimates for 
gender (binary) were based on a total sample size (N) of 99, with a P0 = 0.01 and frequency of 
X= 1 was 10%.  Power estimates for body mass index (BMI; continuous) were assessed per 
kg/m2 and based on N = 99 and P0 = 0.01.  Power estimates for smoking duration (continuous) 
were assessed per 10 years of smoking and based on N = 99 and P0 = 0.02.  Power calculations 
for alcohol intensity was determined separately for light/moderate drinkers and heavy drinkers 
compared to never drinkers.  Estimates for light/moderate drinkers (binary) were based on N = 
69, P0 = 0.01 and frequency of X=1 was 44%; and for heavy drinkers (binary) were based on N 
= 55, P0 = 0.01 and frequency of X= 1 was 30%.  Power estimates for denture use (binary) were 
based on N = 99, P0 = 0.01 and frequency of X=1 was 46%.  Power estimates for stage at 
diagnosis (binary) were based on N = 96, P0 = 0.02 and frequency of X=1 was 67%.  Power 
estimates for daily fruit and vegetable consumption (continuous) were assessed per log-daily 
serving and based on N = 99 and P0 = 0.01. 
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Table 21.  Power calculations for the assessment of miR-137 promoter methylation risk factors in oral rinses 
from SCCHN patients 
 
 
 
C.3.3 Association of miR-137 Promoter Methylation and SCCHN Prognostic Factors 
Statistical power for the association of miR-137 promoter methylation in tumor tissue and 
prognostic factors (where the prognostic factors are the outcome) was calculated using the 
logistic regression function of PASS 2008 (NCSS, Kaysville, UT) for detection of odds ratios of 
1.5, 2.0, 2.5 and 3.0 (Table 22), where alpha = 0.05.  Frequency of the primary predictor (miR-
137 methylation) = 16%, except for the estimates for tumor margins, where it = 14%.  Power 
estimates for T-stage (binary) were based on total sample size (N) of 67 and baseline probability 
event probability (P0; based on model intercept coefficient) = 0.48; N = 67 and P0 = 0.54 for 
nodal positivity (binary); N = 67 and P0 = 0.71 for stage at diagnosis (binary); N = 62 and P0 = 
0.21 for tumor grade (binary); and N = 50 and P0 = 0.16 for tumor margins. 
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Table 22.  Power calculations for the association of miR-137 promoter methylation and SCCHN prognostic 
factors 
 
 
 
C.3.4 Association of miR-137 Promoter Methylation and SCCHN Survival 
Statistical power for the multivariable Cox proportional hazards models for the association of 
miR-137 promoter methylation and survival were estimated (Table 23) using the stpower cox 
function in Stata 11 (StataCorp, College Station, TX).  A total sample size of N = 67 was used to 
produce power estimates for hazard ratios of 1.5, 2.0, 2.5 and 3.0.  For overall survival, the 
probability of failure (death) = 0.21; and for disease-free survival, the probability of failure 
(recurrence) = 0.13. 
 
Table 23.  Power calculations for the association of miR-137 promoter methylation and SCCHN survival 
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APPENDIX D: PROJECT 1 QUESTIONNAIRE 
D.1 PROJECT 1 QUESTIONNAIRE VARIABLE LIST 
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D.2 PROJECT 1 QUESTIONNAIRE 
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